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ABSTRACT  
Background. Genome wide association studies (GWAS) have played a primary 
role in demonstrating that genetic variation in a number of loci, as assessed by 
single nucleotide polymorphisms (SNPs), affects the risk of type 2 diabetes 
mellitus (T2DM). Among these, rs7903146, an intronic variant of the TCF7L2 
(Transcription Factor 7 Like 2) gene, is possibly the strongest known genetic risk 
factor for T2DM (O.R.=1.37). Each risk variant, however, per se contributes 
quantitatively little to the overall risk and is often of questionable biological 
significance in affecting the determinants of glucose regulation. 
Aim(s). To elucidate the effects of several T2DM risk genetic loci on clinical and 
pathophysiological (beta-cell function and insulin sensitivity) phenotypes of 
patients with newly diagnosed T2DM.  
Methods. We studied 464 patients of Italian ancestry with newly diagnosed, 
GAD-antibody negative, type 2 diabetes mellitus. Standard clinical phenotyping 
was carried out by classical methods. Beta-cell function and insulin sensitivity 
were assessed by mathematical modeling of glucose and C-peptide curves during 
a 240’ frequently sampled OGTT and by euglycemic insulin clamp, respectively. 
Beta-cell function is described as the sum of two components: i. first phase of 
insulin secretion or derivative control (DC), presented as the pulse secretory 
response to a unit rate of change in glucose concentration; ii. second phase of 
insulin secretion or proportional control (PC), presented as the insulin secretion 
rate at glucose concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mM, respectively. 
Insulin sensitivity is presented as the amount of glucose infused which is 
metabolized in the last 60’ of the euglycemic clamp (M value). The following 
SNPs (related gene in brackets), already known to be risk loci of T2DM, were 
genotyped: rs7901695 (TCF7L2), rs7903146 (TCF7L2), rs11196205 (TCF7L2), 
rs12255372 (TCF7L2), rs679931 (CACNA1E), rs1801282 (PPARG), rs1044498 
(ENPP1), rs10946398 (CDKAL1), rs1111875 (HHEX/IDE) rs10010131 (WFS1), 
rs4430796 (TCF2), rs4402960 (IGF2BP2).  
Results.  
 TCF7L2. The risk alleles of 3 (rs7901695, rs7903146, rs11196205) out of 
4 TCF7L2 SNPs were associated with higher fasting plasma glucose (p<0.01, 
p<0.03 and p<0.01 respectively). The risk alleles of the first two SNPs 
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(rs7901695, rs7903146) were associated to a decrease in the proportional control 
of beta-cell function (p<0.02 and p<0.03 respectively). Four TCF7L2 haplotypes 
were detected, two of which (haplo4, frequency: 0.038; and haplo9, frequency: 
0.086) had a strong impact on beta-cell function. Haplo4 was associated with the 
lowest proportional control of beta-cell function while haplo9 showed the highest. 
 Other genetic variants. None of the 8 remaining SNPs (rs679931, 
rs1801282, rs1044498, rs10946398, rs1111875, rs10010131, rs4430796, 
rs4402960) showed any significant independent association with insulin 
sensitivity or beta-cell function. We computed a genetic risk score of this variants, 
by summing the number of the T2DM risk alleles present in each patient 
(excluding TCF7L2). The patients were divided into three groups: 6 or less risk 
alleles (group A, n=76), 7-9 risk alleles (group B, n=226), 10 or more risk alleles 
(group C, n=69). The porportional control of beta-cell function was significantly 
impaired (P=0.05) in group C than in the other two groups, i.e. the higher the 
number of T2DM risk variants the lower beta cell function.  
Conclusions. These data show that several genetic variants play a significant role 
in determining the pathophysiological phenotype of patients with newly 
diagnosed type 2 diabetes, with most of the influence exerted on beta-cell 
function. Thus, assessment of T2DM risk genotype may turn to be useful for 
diagnostic, prognostic and therapeutic purposes in patients with newly diagnosed 
T2DM. 
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ABSTRACT 
Introduzione. Negli ultimi anni sono stati individuati molti nuovi polimorfismi 
(SNP, Single Nucleotide Polymorphisms) associati allo sviluppo di diabete di tipo 
2 (T2DM), soprattutto grazie all’avvento di nuove tecniche di genotipizzazione su 
larga scala, GWAS (Genome Wide Association Scan). 
Ogni SNP però contribuisce da solo in modo marginale al rischio di sviluppare la 
malattia e spesso è poco chiara la funzione biologica di queste varianti geniche 
nella regolazione dell’omeostasi del glucosio. Tra questi polimorfismi, la variante 
intronica rs7903146 del gene TCF7L2 (Transcription Factor 7 Like 2) è al 
momento il più forte fattore di rischio per il diabete di tipo 2 (O.R.= 1.37). 
Scopo dello studio. Chiarire l’effetto di diversi loci associati allo sviluppo di 
T2DM su fenotipi clinici e patofisiologici (funzione beta-cellulare e sensibilità 
insulinica) in pazienti con T2DM neo-diagnosticato. 
Metodi. Abbiamo analizzato 464 pazienti di discendenza italiana con T2DM neo-
diagnosticato, anti-GAD negativi. La caratterizzazione clinica standard è stata 
effettuata mediante metodi classici. 
La funzione beta-cellulare è stata valutata applicando un modello matematico alle 
curve di glucosio e di C-peptide derivanti da prelievi eseguiti durante OGTT, ed è 
differenziabile in due componenti: prima fase di secrezione insulinica o controllo 
derivativo, rappresentato dalla quantità di insulina secreta in risposta 
all’incremento unitario della concentrazione di glucosio, e la seconda fase di 
secrezione o controllo proporzionale, rappresentato come la velocità di secrezione 
insulinica a concentrazioni crescenti di glucosio (5.5, 8.0, 11.0, 15.0 and 20.0 mM 
). La misura della sensibilità insulinica deriva dalla quantità di glucosio infuso che 
viene metabolizzato negli ultimi 60 minuti del clamp euglicemica, tale valore è 
detto M. 
Sono stati genotipizzati i seguenti SNP, già visti essere associati allo sviluppo di 
T2DM: rs7901695 (TCF7L2), rs7903146 (TCF7L2), rs11196205 (TCF7L2), 
rs12255372 (TCF7L2), rs679931 (CACNA1E), rs1801282 (PPARG), rs1044498 
(ENPP1), rs10946398 (CDKAL1), rs1111875 (HHEX/IDE) rs10010131 (WFS1), 
rs4430796 (TCF2), rs4402960 (IGF2BP2). 
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Risultati. 
TCF7L2. Gli alleli di rischio di 3 su 4 polimorfismi di TCF7L2 
(rs7901695, rs7903146, rs11196205) sono associati a più alti valori plasmatici di 
glucosio a digiuno (p<0.001, p<0.03 e p<0.01 rispettivamente). Gli allele di 
rischio dei primi due SNP (rs7901695 e rs7903146) sono associati ad un aumento 
del controllo proporzionale della funzione beta cellulare (p<0.02 e p<0.03 
rispettivamente). Tramite l’analisi degli aplotipi sono stati individuati 4 aplotipi 
rappresentati nella popolazione in esame e due di questi (haplo4, frequenza: 0.038 
e haplo9, frequenza: 0.086) hanno un forte impatto sulla funzione beta-cellulare. 
Altre varianti geniche. Nessuno dei rimanenti 8 polimorfismi (rs679931, 
rs1801282, rs1044498, rs10946398, rs1111875, rs10010131, rs4430796, 
rs4402960) ha mostrato associazione indipendente con alterazioni della funzione 
beta-cellulare o della sensibilità insulinica. Abbiamo calcolato uno score genetico 
di queste varianti sommando il numero di alleli di rischio presenti in ogni paziente 
(escludendo TCF7L2). I pazienti sono stati divisi in tre gruppi: portatori di un 
numero di alleli di rischio ≤ 6 (gruppo A, n=76), pazienti con un numero di alleli 
di rischio compresa tra 7 e 9 (gruppo B, n=226) e soggetti con un numero di alleli 
di rischio ≥ 10 (gruppo C, n=69). Il controllo proporzionale della funzione beta-
cellulare risultava alterato in modo statisticamente significativo (p=0.05) nel 
gruppo C rispetto agli altri due gruppi. Maggiore è il numero di alleli di rischio 
associato a T2DM, peggiore è la funzione beta-cellulare. 
Conclusioni. Questi dati mostrano come diverse varianti geniche giocano un 
ruolo significativo nel determinare il fenotipo patofisiologico dei pazienti con 
T2DM neo-diagnosticato, influenzando soprattutto la funzione beta-cellulare. 
Perciò, la valutazione dei genotipi di rischio per il T2DM potrebbe tornare utile 
per scopi diagnostici, prognostici e terapeutici in pazienti con T2DM neo-
diagnosticato. 
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INTRODUCTION 
Diabetes mellitus affects approximately 200 million people around the world and 
it is forecasted that by 2025 this number would be doubled. Because of its 
widespread distribution and increasing prevalence in modern society, great efforts 
have been made to understand the underlying causes of the disease.  
Approximately 95-98% of patients with diabetes mellitus are affected by either 
type 1 (3-7%) or type 2 diabetes (T1DM and T2DM respectively). By definition, 
they are both characterised by raised plasma glucose levels.  
Normal glucose homeostasis depends on the balance between glucose production 
by the liver and glucose absorption by the gut, on one side, and glucose uptake by 
the brain, kidney, liver itself, muscle, and adipose tissue, on the other side. 
Insulin, the predominant anabolic hormone involved, increases the uptake of 
glucose from the blood, enhances its conversion to glycogen and triglycerides, 
and also increases glucose oxidation. Plasma glucose levels are normally kept 
within a small range (4 to 6 mmol/l) by multiple mechanisms. After a meal, a 
small increase in plasma glucose will lead to an increased insulin secretion by the 
pancreatic β-cells. This is associated with a decrease in glucose production by the 
liver and enhanced glucose uptake in muscle and adipose tissue. These actions 
result from a combination of short term rapid effects and longer term slow effects, 
which involve changes in gene transcription and in the rate of translation of 
enzymes involved in glycogen synthesis, the glycolytic pathway, and lipid 
metabolism. There are a number of glucose counterregulatory hormones, the main 
one is glucagon, and the balance between the insulin action and the effects of the 
counterregulatory hormones ensures normal glucose homeostasis. 
Both type 1 and type 2 diabetes mellitus show a familial predisposition, which is a 
strong indication for the involvement of genes in people’s susceptibility to the 
disease. However, the aetiology underlying types 1 and 2 is different and different 
genes are likely to be involved in each type of diabetes mellitus. 
As the major cause of Type 1 diabetes mellitus is the autoimmune destruction of 
the pancreatic β cells, this form of diabetes usually appears or is first diagnosed in 
young people and was known as “juvenile diabetes”. Type 2 diabetes, which 
accounts for around 90% of all cases of diabetes mellitus, usually develops after 
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the age of 40, and it was referred to as "adult onset diabetes mellitus". Unlike 
Type 1, Type 2 diabetes is not caused by autoimmune destruction of the 
pancreatic β-cells, but appears to be caused by a number of different defects in 
both insulin action and insulin secretion.  
There are many long term complications associated to diabetes mellitus, generally 
divided into micro- and macrovascular complications. These long term chronic 
complications have a severe impact on health and quality of life of patients and 
represent a quite important problem for the entire society. Microvascular 
complications include retinopathy, neuropathy, and nephropathy, with type 2 
diabetes mellitus being one of the main causes of blindness, lower limb 
amputations, and renal failure in adults. As to macrovascular complications, 
suffice it to say that type 2 diabetes mellitus is a major risk factor for 
cardiovascular morbidity and mortality. These chronic complications have a high 
socioeconomic cost and put a heavy burden on public health services [1]. 
Since type 2 diabetes mellitus (T2DM) is a complex disease, both environmental 
and genetic factors are involved in the development of the disease. Environmental 
factors of particular importance include overweight/obesity, increased amount of 
body fat, hypertension, dyslipidemia, lack of physical exercise. Regarding the 
genetic factors, there is ample evidence that T2DM has a strong genetic 
component, as long appreciated by physicians because of the role as risk 
indicators of family history of diabetes and of ethnicity.  
Despite strenuous efforts over the past two decades to identify the genetic variants 
that contribute to individual differences in predisposition to T2DM, slow progress 
and limited success have been obtained until recently. Two different methods 
have been used to discover genes that are related to a disease: analysis of genomic 
regions shared by relatives more often than expected (so called linkage analysis 
using polymorphic markers such as microsatellites or tandem repeats) and 
candidate gene studies, particularly by attempts to correlate biological variation 
(phenotype) with variation in DNA sequences (genotype) in the form of a single 
nucleotide polymorphism (SNP) [2]. The advent of genome-wide association 
(GWA) analysis has allowed researchers to uncover variants influencing complex, 
common phenotypes – including T2DM – and has resulted in the identification of 
a growing number of trait susceptibility loci [3]. 
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PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS. 
The main pathophysiologic factors in type 2 diabetes are defects in both β cell 
function and insulin sensitivity. 
β-cell function and insulin action. 
Insulin is produced by β-cells located in the pancreatic islets. A human pancreas 
contains ~1 million pancreatic islets that are distributed throughout the exocrine 
parenchyma of the gland. Every pancreatic islet contains ~1,000 endocrine cells of 
which 75% are insulin-producing β-cells. Insulin is synthesised as pro-insulin in 
the endoplasmic reticulum and is processed to the biologically active form inside 
the secretory granules. The granules are small membrane-bound secretory 
granules with a diameter of ~0.35 µm. Insulin can be stored within the granules 
for several days prior to its release. Within the granules, insulin is present as a 
Zn2+-insulin crystal, the stability of which depends on an acidic intragranular pH. 
Upon fusion of the secretory granule with the plasma membrane, the pH within 
the granule equilibrates with that in the exterior resulting in the dissolution of the 
crystal and the liberation of insulin. The β-cells receive a rich vascular supply 
which empties into the portal vein and the liver is the first organ to be exposed to 
the newly-released insulin.  
The β-cell is electrically excitable and uses changes in membrane potential to 
couple variations in blood glucose to changes in insulin secretion. Stimulation-
secretion coupling in β-cells is different from other cell types because, instead of 
being mediated by receptor binding, glucose needs to be transported (GLUT2-
glucose transporter 2) into the cytoplasm and metabolized to stimulate exocytosis. 
The β-cell contains many different ion channel proteins (each present in 100–
5,000 copies per β-cell) but two types of ion channels are particularly important 
for the initiation of insulin secretion, KATP-channels and Ca2+-channels.  
The Kir6.2-SUR1 complex, now known as the KATP channel, acts as a regulated 
K+channel, binding ATP. KATP-channels are active at low glucose concentrations, 
presumably because of the high intracellular ADP levels, which stimulate channel 
activity. During fasting, basal glucose levels are ~4-5 mM, and the β-cell 
membrane is polarized at resting potential. The resting potential in β-cells is 
mainly due to the activity of ATP-sensitive potassium (KATP) channels and an 
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electrogenic Na+-K+-ATPase pump that preserves the cationic gradient. When 
glucose is low or absent in the extracellular medium, the resting potential of 
isolated β-cells is around -70 to -80 mV.  
It is well accepted that when glucose concentration rises a first phase of coupling 
is observed, where glucose enters the cell and is metabolized, leading to a rise in 
the ratio of ATP to ADP and closure of KATP channels. These channels act as 
metabolic sensors, because they close in response to changes in the nucleotide 
concentration (ATP/ADP) that result from glucose metabolism. KATP closure 
initiates a slow depolarization of the membrane potential that, when it reaches 
around -40 mV, increases the open probability of Na+ and Ca2+ voltage-dependent 
channels, increasing Na+ and Ca2+ entry into the cells and causing further 
depolarization. Around -20 mV, high-voltage Ca2+-dependent channels open, and 
this leads to a larger increase in [Ca2+]i and subsequent insulin exocytosis (Fig. 
1). 
 
        
 
Fig. 1 At low glucose concentrations, ATP-sensitive potassium (KATP) channels are open and are 
responsible for the membrane potential. At high glucose concentration KATP channels are close and 
calcium arises inside the cell, causing membrane depolarization and consequently insulin release 
from the granules. 
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Biphasic insulin secretion  
Insulin secretion in response to changes in extracellular glucose concentrations is 
biphasic both in vitro (Fig.2) and in vivo.  
The first phase results from exocytose of granules from the "Readily Released 
Pool” (RRP). This glucose-induced first-phase insulin release is considered to be 
due to the fact that the KATP channel–dependent elevation of [Ca2+]ic 
(intracellular) promotes fusion of the β-granules already in the RRP. This phase of 
insulin secretion accounts for only about 5-10% of the total released after a meal. 
The second phase, characterized by a gradual increase of insulin release following 
the initial peak, requires ATP and leads to the movement of the granules from the 
Reserve Pool (RP) to the RRP. β-granules in the cell do not constitute a uniform 
population. A majority of them remain inside the cell and cannot immediately be 
releasable, thus forming a reserve pool, whereas a small portion of them constitute 
the RRP, which is available for immediate secretion. This slow phase is the major 
contributor to insulin release. Maximal quantities of insulin are released after 
about 60 minutes. 
Upon elevation of extracellular glucose, Ca2+-induced fusion of granules already 
in the RRP occurs within minutes, and expansion and/or replenishment of the 
RRP from the RP is in progress several minutes later [4].  
 
 
Fig. 2 Profile of glucose-induced insulin secretion. Glucose was elevated to 11 mM as indicated 
by horizontal bar. There is a rapid first phase (lasting ~10 min) and a slower second phase [5]. 
 
 
Introduction 
- 11 - 
Insulin action. 
After being secreted by the pancreas, insulin is released in to the bloodstream, it is 
delivered to its target cells throughout the body, and it binds to specific receptors 
to elicit insulin-dependent biological responses.  
The insulin receptor is a tyrosine kinase. It functions as an enzyme that transfers 
phosphate groups from ATP to tyrosine residues on intracellular target proteins. 
Binding of insulin to the alpha subunits of the receptor causes the beta subunits to 
phosphorylate themselves (autophosphorylation), thus activating the catalytic 
activity of the receptor. The activated receptor then phosphorylates a number of 
intracellular proteins, which in turn alter their activity, thereby generating a 
biological response. 
- Insulin and carbohydrate metabolism 
Insulin facilitates entry of glucose into muscle, adipose and several other tissues. 
When insulin concentrations are low, the glucose transporters GLUT4 are located 
in cytoplasmic vesicles, where they are useless for transporting glucose. Binding 
of insulin to receptors on such cells leads rapidly to fusion of those vesicles with 
the plasma membrane and insertion of the glucose transporters, thereby giving the 
cell an ability to efficiently take up glucose, which can be used as a source of 
energy for the cells. When blood levels of insulin decrease and insulin receptors 
are no longer occupied, the glucose transporters are recycled back into the 
cytoplasm. 
There are some tissues that do not require insulin for efficient uptake of glucose: 
important examples are brain, liver, red blood cells ad kidney. This is because 
these cells do not use GLUT4 for importing glucose, but rather, other transporters 
which are not insulin-dependent. 
Insulin also stimulates liver and muscle to store glucose in the form of glycogen. 
So when the supply of glucose is abundant, insulin "tells" the liver and the muscle 
to bank as much of it as possible in order to use it later. 
- Insulin and lipid metabolism. 
Insulin promotes synthesis of fatty acids in the liver. Indeed when the liver is 
saturated with glycogen, any additional glucose taken up by hepatocytes is 
Introduction 
- 12 - 
shunted into pathways leading to synthesis of fatty acids, which are exported from 
the liver as lipoproteins. These lipoproteins, after being released in the circulation, 
provide free fatty acids for use in other tissues, including adipocytes, which use 
them to synthesize triglyceride.  
Insulin also inhibits breakdown of fat in adipose tissue by inhibiting the 
intracellular hormone sensitive lipase which hydrolyzes triglycerides to release 
fatty acids and glycerol. It also facilitates entry of glucose into adipocytes, and 
within those cells, glucose can be used to synthesize glycerol. Glycerol, along 
with the fatty acids delivered from the liver, is used to synthesize triglycerides 
within the adipocyte. By these mechanisms, insulin is involved in further 
accumulation of triglycerides in fat cells.  
 
Beta-cell function in T2DM. 
Type 2 diabetes involves defects of insulin secretion, manifested as a loss of first 
phase and a reduction of second phase. The insulin secretory defect could result 
from either defects of β-cell function or a reduction in β-cell mass or both. 
It is well known that patients with type 2 diabetes and those with impaired glucose 
tolerance exhibit a delayed response to a glucose load. While these patients 
produce apparently sufficient quantities of insulin in response to a challenge, 
secretion is not properly timed. The initial rapid rise in blood glucose does not 
elicit the usual "insulin spike"; the rapid first phase is reduced or lacking. Because 
of the lack of correlation between carbohydrate uptake from meals and timing of 
insulin secretion, these patients experience hyperglycemic periods after meals. 
Type 2 diabetes has been proposed to result from a combination of a genetic 
predisposition, aging, lifestyle and obesity. The gene variants predisposing to type 
2 diabetes may be expected to have mild effects on β-cell function and even in the 
case several negative polymorphisms are present simultaneously, they may not 
influence β-cell function sufficiently to produce type 2 diabetes unless other 
factors come into play.  
Elevated plasma levels of both FFAs (Free Fatty Acid) and glucose represent 
hallmarks of type 2 diabetes. Both have been postulated to contribute to the 
insulin secretion defect. Chronic exposure of islets to an excess of either glucose 
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or lipids impairs insulin secretion. There is a strong negative correlation between 
plasma glucose levels and insulin secretion.  
This complex relationship between glucose and beta-cell function may be 
underlied also by a dedifferentiation of the β-cell so that key regulatory genes 
become either down- or up-regulated. Once insulin secretion show initial 
impairments, a vicious cycle comprising a slight increase in plasma glucose levels 
with subsequent progressive impairment of glucose-induced insulin secretion 
results. 
The molecular mechanisms by which high FFAs interfere with glucose-induced 
insulin secretion remain obscure. It is important to emphasise that obesity and 
elevated FFA levels do not result in type 2 diabetes by default. It is therefore 
evident that other factors must be important, including a strong genetic component 
(see the section Genetics of type 2 diabetes). A very significant observation in this 
context is that a sustained increase in plasma FFAs (by lipid infusion) resulted in 
marked suppression (1st phase insulin secretion reduced by 60%) of insulin 
secretion only in individuals with a family history of type 2 diabetes [6]. 
 
Insulin sensitivity. 
Insulin sensitivity could be defined as the systemic response of the body to the 
glucose lowering action of insulin. It represents the ability of endogenous insulin 
to reduce glucose in extracellular fluids by inhibiting glucose release from the 
liver and stimulating the uptake of glucose from peripheral tissues. 
As I mentioned above, insulin acts at the surface of insulin-dependent cells to 
cause the insertion in the plasma membrane, from within the cell, of special 
protein molecules – the so-called GLUT-4 transporters. The GLUT-4 transporters 
rise to the cells' outer membranes where they grab hold of the glucose molecule 
and transport it into the interior of the cell. Here the glucose is used to produce 
energy and any excess is converted into fat. 
This process functions perfectly in non-diabetic persons resulting in a steady 
glucose level in the blood stream usually between 60 and 115 mg/dL with an 
average of 85 mg/dL. Patients with type 2 diabetes usually produce an adequate 
amount of insulin, but for some reason the mechanism whereby the insulin 
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summons the GLUT-4 transporters does not function. This state is called insulin 
resistance and is characterized by an inability of insulin to lower plasma glucose 
levels through suppression of hepatic glucose production and stimulation of 
glucose utilization in skeletal muscle and adipose tissue. The result is that both 
glucose and insulin levels in the blood remain high (Fig. 3).  
In diabetics glucose levels are not under control and can reach levels of 250 
mg/dL or higher. Up to 75% of insulin-dependent glucose disposal occurs in 
skeletal muscle, whereas adipose tissue accounts for only a small fraction.  
 
 
Fig. 3 Defects in insulin signaling to GLUT4 could cause insulin resistance. 
 
 
Both obesity and lipoatrophy also cause insulin resistance and predisposition to 
type 2 diabetes, demonstrating that adipose tissue is crucial in regulating 
metabolism beyond its ability to take up glucose. In the liver, insulin blocks 
glycogenolysis and gluconeogenesis, and stimulates glycogen synthesis, thereby 
regulating fasting glucose levels. 
Obesity is clearly a major risk factor, but in some cases of extreme obesity in 
humans and animals, insulin sensitivity is normal. 
Adipose tissue has a special role in insulin resistance. Circulating FFAs derived 
from adipocytes are elevated in many insulin-resistant states and have been 
suggested to contribute to the insulin resistance of diabetes and obesity by 
inhibiting glucose uptake, glycogen synthesis and glucose oxidation, and by 
increasing hepatic glucose output. Elevated FFAs are also associated with a 
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reduction in insulin-stimulated IRS-1 phosphorylation and IRS-1-associated 
PI(3)K (phosphatidylinositol-3-OH kinase) activity [7]. 
Not long ago, it seemed plausible that insulin resistance resulted from a defect 
inherent in the insulin signaling pathway, indeed there is only a single insulin 
receptor, and individuals who lack it or have antibodies against it develop severe 
insulin resistance. However intrinsic receptor defect does not explain the link 
between obesity and insulin resistance; indeed, as insulin enhances fat storage, 
insulin resistance in adipose tissue might be expected to mitigate obesity.  
An alternative theory postulates that insulin resistance arises when pathological 
levels of humoral factors disrupt insulin signaling in responsive tissues. This 
humoral theory emerged from the recently recognized role of adipose tissue as a 
secretory organ, and provided an obvious link between obesity and insulin 
resistance. It now seems that the adipose tissue secretes many factors—
collectively termed ‘adipokines’—that include adiponectin, resistin, retinol 
binding protein 4 and numerous classical cytokines including interleukin IL-6. In 
obesity, secretion of these factors is dysregulated in a way that is generally 
detrimental to insulin action on peripheral tissues. Some adipokines are involved 
in innate immunity and are also produced by macrophages. Remarkably, bone 
marrow–derived macrophages home to adipose tissue in obesity. Increased 
secretion of resistin and cytokines by adipocytes and macrophages in adipose 
tissue, together with decreased adipocyte secretion of the insulin-sensitizing 
hormone adiponectin, all contribute to the development of insulin resistance in 
muscle and liver.  
Another hypothesis is that inflammation can cause insulin resistance. In fact it has 
been reported that increased NF-κB (a transcription factor involved in 
inflammatory events) activity is associated with increased expression of the genes 
that encode several cytokines and causes insulin resistance. These observations 
strongly support the idea that the inflamed liver can be the primary source of 
humoral factors that cause systemic insulin resistance. So the liver, in addition to 
adipose tissue, can be the primary source of factors that cause insulin resistance 
[8]. 
In figure 4 it is shown how β-cell dysfunction and insulin resistance could lead to 
hyperglycaemia and increased circulating fatty acid in type 2 diabetes. 
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Fig. 4 Decreased insulin secretion will reduce insulin signalling in its target tissues. Insulin 
resistance pathways affect the action of insulin in each of the major target tissues, leading to 
increased circulating fatty acids and hyperglycaemia of diabetes. In turn, the raised concentrations 
of glucose and fatty acids in the bloodstream will feed back to worsen both insulin secretion and 
insulin resistance
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GENETIC FACTORS INVOLVED IN TYPE 2 DIABETES. 
The field of type 2 diabetes genetics had until recently succeeded in identifying 
few genuine disease susceptibility variants. A susceptibility locus is a genomic 
fragment of DNA that could be considered a genetic factor involved in the 
development of a complex and multigenic disease like T2DM. The presence of a 
susceptibility variant in this locus, together with environmental factors, increases 
the risk of T2DM.  
There is ample evidence that T2DM has a strong genetic component. The 
concordance of T2DM in monozygotic twins is approximately 70% compared 
with 20–30% in dizygotic twins. The life-time risk of developing the disease is 
about 40% in offspring of one parent with T2DM the risk approaching 70% if 
both parents have diabetes. Large ethnic differences in the prevalence of T2DM 
have also been ascribed to a genetic component [2]. 
Traditionally, two different methods have been used to discover genes that are 
related to a disease: analysis of genomic regions shared by relatives more often 
than expected, the so called linkage analysis, and the candidate gene studies, but, 
as to T2DM, little results have been obtained from the use of both of them. The 
advent of genome-wide association (GWA) scans has transformed the situation, 
leading to an expansion in the number of established, robustly replicated T2DM 
loci to almost 30 [9, 10]. 
 
Linkage analysis. 
Genetic linkage occurs when particular genetic loci or alleles for genes are 
inherited jointly. Genetic loci on the same chromosome which are physically close 
to one another tend to stay together during meiosis, and are thus genetically 
linked. Because there is some crossing over of DNA when the chromosomes 
segregate, alleles on the same chromosome can be separated and go to different 
daughter cells. There is a greater probability of this happening if the alleles are far 
apart on the chromosome, as it is more likely that a cross-over will occur between 
them. By working out the number of recombinants it is possible to obtain a 
measure for the distance between the genes. This distance is called a genetic map 
unit (m.u.), or a centimorgan, and is defined as the distance between genes for 
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which one product of meiosis in 100 is recombinant. A recombinant frequency 
(RF) of 1 % is equivalent to 1 m.u.  
A linkage map is created by finding the map distances between a number of traits 
that are present on the same chromosome. Linkage mapping is critical for 
identifying the location of genes that cause genetic diseases. The success of 
identifying T2DM susceptibility genes by linkage has been restricted to the story 
of one single gene: CAPN10, which was found to be associated with type 2 
diabetes mellitus in Mexican Americans, in the NIDDM1 region. The mechanisms 
by which calpain10 is involved in the development of T2DM is not yet clear, but 
it could be possible that polymorphisms located in this gene alter the calpain-
regulated gene expression [11, 12] 
Second to CAPN10, TCF7L2 (Trascription Factor 7 Like 2) is one of the earliest 
examples of a gene discovered to be associated with T2DM without prior 
knowledge of its function as a basis for its candidacy. TCF7L2 was identified in a 
follow-up analysis of a region on chromosome 10q identified through linkage 
analysis. TCF7L2 is involved in Wnt signaling and in the transcription of a 
number of genes. [2, 13]  
TCF7L2 variants and their association with T2DM will be discuss later in this 
section. 
 
Candidate gene approach. 
The starting point for the candidate gene approach is the potential implications 
that either altered expression and/or function of a particular gene product 
(conferred by intronic or exonic genetic variants) may have on a biological 
function or disease. Defects in genes encoding proteins that play a role in 
pathways involved in insulin control and glucose homeostasis are excellent 
candidates for type 2 diabetes mellitus. To date, many candidate genes have been 
studied for their role in type 2 diabetes. The majority of these studies have failed 
to uncover any association [1-3, 9]. The first two genes identified through this 
approach that have been confirmed to be associated with T2DM are PPARG 
(Peroxisome Proliferator-Activated Receptor Gamma) [14] and KCNJ11 
(Potassium Channel, Inwardly Rectifying, Subfamily J, Member 11) [15]. 
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More recently other few genes have been demonstrated to be associated with 
T2DM through the gene-candidate approach: WFS1 (Wolfram Syndrome 1, 
involved in the Wolfram Syndrome) [16], TCF2 (Transcription Factor 2, involved 
in the Maturity-Onset Diabetes of the Young (MODY) 5) [17] and ENPP1 
(Ectonucleotide Pyrophosphatase/Phosphodiesterase1, the product of which is 
known to modulate insulin-receptor function) [18]. 
 
GWAS (Genome Wide Association Scan) 
The last few years have seen substantial changes in the way genetic association 
studies are conducted. The advent of the GWA approach was the result of at least 
three components. The first was delivery of a catalogue of patterns of human 
genome-sequence variation through the efforts of the International HapMap 
Consortium (http://www.hapmap.org) [19]. 
In the Hapmap website all the SNPs identified until now are collected and also 
information is provided about them, such as allele frequency in 4 different 
population (Yoruba, Chinese, Japanese and individuals with ancestry from 
Northern and western Europe) and Linkage Disequilibrium (LD) values between 
different SNPs. The presence of LD among SNPs allows to reduce the number of 
independent genetic tests required to survey the genome, such that about 80% of 
all common variation could be sampled with as few as 500,000 carefully chosen 
SNPs. 
The second important factor is represented by the new genotyping methods that 
allow to perform massively parallel SNP-typing at high accuracy and low cost. 
Finally the availability of large sample collections has led to increased power in 
both discovery and replication studies. 
In addition to TCF7L2, PPARG, KCJN11 and WSF1 the first GWAS have 
identified at least six novel genes/loci for T2DM: CDKN2A and CDKN2B 
encoding the tumor suppressors cyclin-dependent kinase inhibitor-2A and -2B 
which may play a role in pancreatic islet regenerative capacity through inhibition 
of CDK4 and CDK6 (cyclindependent kinase 4 and 6), respectively; IGF2BP2 
which encodes insulin-like growth factor 2 binding protein 2, an mRNA binding 
protein implicated in transport of RNA targets to enable protein synthesis 
Introduction 
- 20 - 
important for pancreas development as judged by studies in Xenopus and 
transgenic mice; CDKAL1 which is homologous to CDK5RAP1, an inhibitor of 
cyclin-dependent kinase CDK5 which transduces glucotoxicity signals in 
pancreatic beta- cells; SLC30A8 (solute carrier family 30,member 8) encoding a 
pancreatic beta-cell specific zinc transporter which may affect insulin stability, 
storage, or secretion; and the HHEX (hematopoietically expressed homeobox) 
region which also harbors IDE, encoding insulin-degrading enzyme which has 
been implicated in both insulin signal and islet function. Both HHEX, critical for 
ventral pancreas development, and IDE are powerful biological candidates for 
T2DM. Moreover FTO (Fat Mass- and Obesity-Associated Gene), already seen to 
be associated with obesity, has been confirmed to be also a T2D-associated locus  
[20-25]. 
GWAS First scan   Replication Confirmed T2DM 
associated loci 
  Cases Controls Population   Cases Controls Population   
Sladek et al [20] 661 614 French   2617 1894 French TCF7L2, SLC30A8, HHEX/IDE 
WTCCC [21] 1924 2938 UK Zeggini 
et al [22] 3757 5346 UK 
TCF7L2, CDKAL1, 
CDKN2A/B,HHEX/IDE, 
SLC30A8, FTO, 
PPARG, KCNJ11 
Scott et al [23] 1161 1174 Finnish   1215 1258 Finnish 
TCF7L2, CDKAL1, 
CDKN2A/B,HHEX/IDE, 
SLC30A8, FTO, 
PPARG, KCNJ11 
DGI [24] 1467 1464 Finnish Swedish   5065 5758 European 
TCF7L2, CDKAL1, 
CDKN2A/B,HHEX/IDE, 
SLC30A8, FTO, 
PPARG, KCNJ11 
3826 12562 European  
1457 986 Hong Kong  Steinthorsdottir 
et al [25] 1399 5275 Icelandic     
865 1106 West Africa  
TCF7L2, CDKAL1, 
CDKN2A/B, 
HHEX/IDE, SLC30A8 
Table 1 T2DM associated loci identified in 2007 by GWAS. 
 
Recent meta-analysis [26] efforts such as DIAGRAM have identified 6 further 
candidate SNPs: JAZF1 (juxtaposed with another zinc finger gene 1) encodes a 
transcriptional repressor of NR2C2 (nuclear receptor subfamily 2, group C, 
member 2); CDC123 (cell division cycle 123 homolog) and CAMK1D 
(calcium/calmodulin-dependent protein kinase 1D), both involved in the cell 
cycle; TSPAN8 (tetraspanin 8) which encodes a cell-surface glycoprotein 
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expressed in carcinomas of the colon, liver and pancreas; THADA (thyroid 
adenoma associated) gene; ADAMTS9 (ADAM metallopeptidase with 
thrombospondin type 1 motif, 9), encoding a widely expressed and secreted 
metalloprotease that cleaves the proteoglycans versican and aggrecan; NOTCH2 
(Notch homolog 2 Drosophila) encoding a type 1 transmembrane receptor 
expressed in embryonic ductal cells of branching pancreatic buds during 
pancreatic organogenesis in mice and ADAM30 (ADAM metallopeptidase domain 
30) that represents the same signal [2]. 
Between the end of 2008 and the beginning of 2009 other two loci have been 
identified to be associated with T2DM: KCNQ1 (Potassium channel, voltage-
gated, KQT-like, member 1) identified in the Japanese population and confirmed 
in European, encoding the pore-forming subunit of a voltage-gated K+ channel 
(KvLQT1) that is essential for the repolarization phase of the action potential in 
cardiac muscle and involved in the onset of T2DM, but through yet unknown 
mechanism [27, 28]; MTNR1B (Melatonin Receptor 1 B), involved in the 
regulation of the circadian rhythms, it has also a role in the regulation of glucose 
homeostasis [29-32].  
A recent meta-analysis [10], focused on loci implicated in fasting glucose 
homeostasis, identified other 5 new loci associated with higher levels of fasting 
glucose and also with increased risk of T2DM: ADCY5 (adenylate cyclase 5) 
catalyzes the generation of cAMP, important for the activation of protein kinase A 
(PKA) and for the insulin secretion process; PROX1 (prospero homeobox protein 
1) encodes a novel co-repressor of hepatocyte nuclear factor 4 (HNF4A) that plays 
a crucial role in beta-cell development; The DGKB-TMEM195 locus, DGKB 
(diacylglycerol kinase catalytic domain β) regulates the intracellular concentration 
of the second messenger diacylglycerol and TMEM195 (transmembrane protein 
195) encodes an integral membrane phosphoprotein highly expressed in liver; 
GCK (glukokinase 4) catalyzes the initial step in utilization of glucose by the 
beta-cell and liver at physiological glucose concentration; GCKR (glucokinase 4 
regulator) is a regulatory protein that inhibits glucokinase in liver and pancreatic 
islet cells by binding non-covalently to form an inactive complex with the 
enzyme. 
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Until now about 30 genes have been identified, but this is an in-progress field and 
other new T2DM associated loci will be found out in the future. 
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TCF7L2 
TCF7L2 has been an important topic of my doctorate studies, so in the following 
chapter I will stop a little bit on it. 
TCF7L2 (Transcription Factor 7 Like 2), also known as TCF-4, is a transcription 
factor involved in the Wnt pathway (Fig. 5) and regulates the transcription of a 
large number of genes.  
There are three known pathways of Wnt signalling; the Wnt/β-catenin (canonical), 
the Wnt/Ca2+ and the Wnt/polarity pathway, which activate distinct intracellular 
signaling pathways, but I will focus just on the first one. In the absence of Wnt 
signaling, glycogen synthase kinase 3β (GSK3b), adenomatous polyposis coli 
protein (APC), axin and β-catenin form components of the ‘destruction complex’, 
enabling GSK3β to phosphorylate β-catenin at serine and threonine residues, 
targeting β-catenin for ubiquitination and degradation by the proteosome. When 
Wnt ligands bind to their receptors (the Frizzled receptors and the LDL receptor-
related protein 5/6 (LRP5/6) co-receptors) Wnt signals are transmitted by the 
association of Wnt receptors with Dishevelled protein (Dvl). This event triggers 
the disruption of the destructive complex, preventing the phosphorylation-
dependent degradation of β-cat, which then enters the nucleus and interacts with a 
member of the TCF family, the protein product deriving from TCF7L2, to form a 
complex that stimulates the β-cat/TCF (or WNT) downstream target genes [33, 
34]. 
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Fig. 5 Wnt/β-catenin signalling pathway [34]. 
 
 
Wnt signaling is a key pathway in cell proliferation and embryogenesis, and it 
also regulates myogenesis and adipogenesis. Defects in this pathway are involved 
also in tumorigenesis.  
Wnt signaling has also been reported to be critical for development of pancreas 
and islets during the embryonic growth, but these findings are quite controversial. 
Indeed, while it is well-known now that this pathway is very important in exocrine 
pancreas development, it is still uncertain its role in the islets development, and 
different studies have been performed in order to point it out. At first it seems that 
Wnt signaling would not be involved in the endocrine pancreas development, 
while other studies showed that the absence of beta-catenin causes defects in 
endocrine pancreas development [34]. Finally a more recent study [35] suggested 
that the conflicting results could be resolved if we assumed that β-cat and β-
cat/TCF exert different functions in a very precise dose-dependent manner at 
different developmental stages. So regulation of Wnt signaling’s timing and 
stimulus is crucial for effects on pancreas development. 
On the basis of these findings it may be less surprising than it was at the time that 
in 2006 a linkage analysis study by Grant and colleagues [13], who were 
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searching for microsatellite associations across a large region of chromosome 10 
previously implicated in T2DM susceptibility, led to the identification of 5 
variants associated with T2DM. This result has been then replicated in many 
different populations [36-41] and also the GWAS published in 2007 [22-24] 
confirmed TCF7L2 association with T2DM.  
Among all the T2D-associated loci discovered until now TCF7L2 is still the one 
with the highest OR (~1,4) and its intronic variant rs7903146, located in exon 3, is 
still the most informative SNP and the one with the strongest association signal. 
Since this variant is intronic it seems that there is no obvious mechanism by which 
it affects the activity of TCF7L2 and there is the possibility that the causal variant 
acts by affecting expression of TCF7L2 rather than altering the structure of the 
expressed protein [42] 
Several potential mechanisms have been proposed to underlie the association 
between TCF7L2 variants and T2DM, including decreased β-cell mass, impaired 
insulin processing or release, impaired GLP1 (Glucagon Like Peptide 1, involved 
in the glucose-stimulated insulin secretion) signalling in β-cells, liver insulin 
resistance and altered chromatin state in T carriers [43-45]. 
Notably, most of the evidence linking TCF7L2 variation to diabetes-related 
intermediate phenotypes in humans has been obtained in nondiabetic individuals. 
Furthermore, with few exceptions [46-49], surrogate markers of beta-cell function 
and/or insulin sensitivity have been used in these human studies. Since both 
insulin sensitivity and β-cell function traits display a significant spread in patients 
with T2DM, the question arises whether TCF7L2 variants may affect beta-cell 
function and/or insulin sensitivity also in diabetic patients, thereby potentially 
being a determinant of T2DM heterogeneity, and/or a marker of the metabolic 
phenotype and/or a tool to select optimal therapy and to better define prognosis. 
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Part of my thesis will focus on the studies performed in order to test whether risk 
polymorphisms and/or haplotypes of TCF7L2 are associated with the clinical and 
metabolic (beta-cell function and/or insulin sensitivity) phenotypes of patients 
with newly diagnosed T2DM.  
To achieve this goal we used the database of the Verona Newly Diagnosed Type 2 
Diabetes Study (Verona NDDS), an ongoing investigation which aims at building 
a biobank of patients with newly diagnosed T2DM. This cohort was deemed 
useful for our purposes because of the absence of the potentially confounding 
effects of long-lasting antidiabetic treatments and of the limited impact of 
duration and severity of hyperglycemia per se on the metabolic phenotypes. 
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“GENETIC LOAD” 
The second part of my thesis will focus on the combined analysis of several 
T2DM-associated loci and follows the footprints of previous studies dealing with 
the additive role played by gene risk variants in shaping T2DM risk. 
As I said above until now TCF7L2 is the locus with the highest OR and its variant 
rs7903146 has the strongest association signal, but by itself it can explain only a 
small part of the phenotypic and metabolic impairments which characterize 
T2DM. And this observation is even more true for all the other identified T2D-
associated polymorphisms with ORs lower than the TCF7L2's one. However, it 
has been demonstrated that these variants are at least additive in determining 
T2DM susceptibility. These studies, indeed, have been conducted in order to test 
whether considering several T2D-associated variants together could explain the 
role of the genetic variants in determining the risk of T2DM [50-54]. It seems that 
genetic information improve very little the knowledge coming from common 
phenotypic and clinical risk factors and they provide only a slightly better 
prediction of risk. However, they could be more helpful if we consider the T2DM 
pathophysiological traits, such as impaired β-cell function and insulin sensitivity, 
instead of the risk of disease. A study by Pascoe and colleagues [47] has showed 
that in nondiabetic subjects, while individual susceptibility alleles only 
moderately alter pancreatic β-cell function, their effect is additively increased 
when they are combined together. 
From these considerations comes the idea to assess the joint gene influence of 
several T2D-associated SNPs on pathophysiological T2DM traits, like β-cell 
function and insulin sensitivity. In agreement with previous studies of T2DM 
genetic epidemiology, we named this putative joint gene influence “genetic load”. 
In the second part of my thesis, therefore, I will describe the results that we 
obtained considering the combined effect of 8 T2D-associated variants (table 2), 
each of which per se devoid of any detectable effect, in determining impairments 
in β-cell function and/or insulin sensitivity in patients with newly diagnosed 
T2DM. 
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SNP NEAREST GENE (chr) ACRONYM FUNCTION 
rs679931 CACNA1E (1) 
Calcium channel, voltage-
dependent, alpha 1E 
subunit 
Voltage-dependent Ca2+ 
channel  
rs1801282 PPARG (3) Peroxisome proliferator-
activated receptor-gamma 
The heterodimer 
PPARG/RXRA is a nuclear 
receptor that regulates 
glucose and lipid 
homeostasis 
rs1044498 ENPP1 (6) 
Ectonucleotide 
pyrophosphatase/ 
phosphodiesterase 1 
It modulates insulin-receptor 
function 
rs10946398 CDKAL1 (6) CDK5 Regulatory subunit 
associated protein 1-like 1 Unknown 
rs1111875 HHEX (10) Haematopoietically 
expressed homeobox 
Involved in Wnt/β-catenin 
pathway, regulation of 
pancreas organogenesis 
rs10010131 WFS1 (4) Wolfram syndrome 1 
Putative transmembrane 
protein highly expressed in 
pancreatic islets,with loss of 
function by mutations in 
Wolfram syndrome 
rs4430796 TCF2 (17) Transcription factor 2 Nuclear transcription factor 
rs4402960 IGF2BP2 (3) Insulin-like growth factor 2 mRNA binding protein 2 
It binds to the 5'-UTR of the 
insulin-like growth factor 2 
(IGF2) mRNAs 
Table 2 List of the considered SNPs, with their location and function.  
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PATIENTS AND METHODS 
Patients. 
Verona Newly Diagnosed Type 2 Diabetes Study (Verona NDDS) 
The Verona NDDS is an ongoing study aiming at building a biobank of patients 
with newly diagnosed T2DM. As of Jan 1 2002, all patients referred to the 
Division of Endocrinology and Metabolic Diseases of University of Verona 
School of Medicine, whose diabetes has been diagnosed in the last six months, are 
asked to participate in this research. The clinical evidence on which the diagnosis 
of type 2 diabetes has been made is reviewed and the diagnosis confirmed [55]. 
Patients already treated with antidiabetic drugs are put on therapy washout for at 
least one week before metabolic tests are performed. Among the exclusion criteria 
are age>75 years, non-Italian ancestry, insulin treatment, presence of GAD 
antibodies, malignancies, and any condition severely impairing liver and/or 
kidney function. The clinical features of the population considered in the two 
studies (TCF7L2 and GENETIC LOAD studies) are reported in table 3 and 9 in 
the RESULTS section. 
Verona Newly Diagnosed Type 2 Diabetes Study  
All subjects consumed a weight-maintaining diet containing 200-250 g of 
carbohydrate/day for at least three days before studies. Body weight was stable in 
all subjects for at least 1 month before studies. No subject participated in any 
heavy exercise. Each subject gave informed written consent before participating 
in the research, which was approved by the Human Investigation Committee of 
the Verona City Hospital. Measurements of standard clinical phenotypes were 
collected in all patients. Metabolic tests were carried out on two separate days in 
random order. On both days, patients were admitted to the Metabolic Clinic 
Research Center at 07:30 after an overnight fast. All studies were carried out in a 
quiet, temperature controlled (22° C) room. 
On one day an OGTT (75 g) was performed to assess beta-cell function. During 
the entire test patients were sitting in a comfortable cardiac chair. One teflon (21 
g) venous catheter was inserted into an antecubital vein for blood sampling and 
kept patent with heparinized normal saline solution. After a 30’ rest to establish 
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baseline and after collecting a 20 cc blood sample for leukocyte DNA extraction, 
at time = 0’ subjects ingested 75 g of glucose in 300 ml of water over 5 min. 
Blood samples to measure glucose, C-peptide and insulin concentrations were 
collected at times -10’, 0’, +15’, +30’, +45’, +60’, +90’, +120’, +150’, +180’, 
+210’ and +240’. In some patients further blood samples were collected at +270’ 
and +300’. Urines were collected to measure glycosuria. 
On a separate day, an euglycemic insulin clamp was performed to assess insulin 
sensitivity [56].During the entire test patients were lying in bed. One teflon 
catheter was introduced into an antecubital vein for the infusion of test substances. 
Another teflon catheter was placed retrogradely into a wrist vein for sampling 
arterialized venous blood, according to the “hot box” technique. After a 30’ rest in 
bed to establish baseline, indirect calorimetry (at least 40’) was performed as 
previously described, for a companion study [57].At the end of calorimetric 
measures, baseline blood samples were collected and a standard euglycemic 
insulin (intravenous prime: 4.8 nmol.min-1.m-2 BSA; continuous infusion: 240 
pmol.min-1.m-2 BSA) clamp was performed [56]. Plasma glucose was allowed to 
decline until it reached 5.5 mmol/l, after which glucose clamping started with a 
glucose concentration goal of 5 mmol/l. The duration of the glucose clamp was at 
least of 120’, but it was prolonged, if and as needed, to ensure at least 60’ of 
insulin clamp at euglycemia in each patient. Timed blood samples were collected 
to measure hormone and substrate levels. In the last 45’ of the clamp indirect 
calorimetry was repeated to assess substrate oxidation and energy production rates 
for a companion study. Urines were collected to measure urea excretion rate. 
In both metabolic tests, all blood samples were collected in pre-chilled tubes and 
readily spun at 1,500 g. Plasma and serum specimens were stored at –80° C. 
Analytical procedures 
Plasma glucose concentration was measured in duplicate on a Beckman Glucose 
Analyzer II (Beckman Instruments, Fullerton, CA, USA) at bedside. Serum C-
peptide and insulin concentrations were measured by chemiluminescence as 
previously described [58]. Glycated hemoglobin and serum lipids were measured 
by standard in-house methods.  
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Calculations 
The amount of glucose metabolized during the last 60 min of the clamp (M value, 
reference insulin sensitivity) was computed with standard formulae [56]. 
The following classical indexes of beta-cell function were computed [59]: 
• Insulinogenic Index: (Insulin30’ – Insulin0’)/(Glucose30’ - Glucose0’), units: 
mU/mmol;  
• CIR120’: Insulin120’/[Glucose120’*(Glucose120’ - 3.89)]; units: mU*L/mmol2.  
Further insights in beta-cell function were sought by mathematical modeling (see 
below). 
Substrate oxidation rates and energy production rate were computed by standard 
formulae as previously described [57]. 
 
Modeling of Beta-Cell Function 
The analysis of the glucose and C-peptide curves during the OGTTs of the Verona 
NDDS follows the general strategy described in previous publications [60, 61] 
with some modifications and builds upon previous works from other laboratories 
[62, 63]. The kinetics of C-peptide is described with a two-compartment model, in 
which the two pools (1 and 2) exchange with each other and the irreversible loss 
of the hormone is from pool 1, the same where C-peptide concentration is 
measured. C-peptide kinetic parameters are computed according to the equations 
by Van Cauter et al.[64]. 
Herein are the equations describing the model of glucose induced insulin secretion 
during an OGTT: 
dcp1(t)/dt = ISR(t) + cp2. k12 – (k01 + k21) . cp1   (Eq.1) 
where ISR = insulin secretion rate, cp1 = C-peptide mass in the sampling 
(accessible) compartment, cp2 = C-peptide mass in the remote compartment, k12 
and k21 = rate constants of the exchange between the two C-peptide 
compartments, and k01 = rate constant of the irreversible loss of C-peptide from 
the accessible compartment. Note that the values of the volume of distribution of 
C-peptide pool 1 (accessible compartment), k12, k21, and k01 are computed 
according to the equations by Van Cauter et al.[64]  
ISR(t) = BSR + DSR (t) + PSR (t) (Eq.2) 
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where BSR = basal insulin secretion rate, DSR = insulin secretion rate due to the 
derivative (or dynamic) component, and PSR = insulin secretion rate due the 
proportional (or static) component. 
BSR = CPss . V1 . k01 (Eq. 3) 
where CPss is basal C-peptide concentration and V1 is the volume of the accessible 
compartment of C-peptide. 
From the modeling viewpoint, DSR(t) and PSR(t) are the components which in 
intravenous glucose tolerance tests or hyperglycemic clamps describe classical 
first phase insulin secretion and second phase insulin secretion, respectively. 
Furthermore, from a physiological viewpoint, the sum of BSR and PSR(t) 
describes the relationship linking glucose concentration and insulin secretion rate, 
in the absence of the derivative component (DSR). 
      DSR(t) and PSR(t) are mathematically defined as follows: 
DSR (t) = X1 (t) . τ-1  (Eq. 4) 
dX1 (t) / dt = σ1 . [dG(t)/dt]/[log(1.1+ t)] - X1(t) . τ-1  if dG(t)/dt > 0 (Eq. 5) 
      dX1(t) / dt = - X1(t) . τ-1        if dG(t)/dt ≤ 0 (Eq. 6)  
where σ1 = glucose sensitivity of derivative control of insulin secretion, G = 
plasma glucose concentration, X1 = C-peptide (insulin) mass made available for 
the derivative component of insulin secretion, τ = time constant of the derivative 
component of insulin secretion, and the term log(1.1 + t) accomodates the time-
associated decline of σ1 documented in humans during a hyperglycemic stimulus 
[65].  
PSR(t) = X2(t) . δ-1 
 
 (Eq. 7)  
dX2(t) / dt = σ2 . [G(t) – θ] - X2 (t) . δ-1  (Eq. 8)  
where  σ2 = glucose sensitivity of the proportional component of insulin secretion, 
X2 = C-peptide (insulin) mass made available for the proportional component of 
insulin secretion, δ = time constant of the proportional component of insulin 
secretion, θ = glucose threshold above which the beta-cell responds with the 
proportional component of insulin secretion to plasma glucose concentration.  
This model was implemented in the SAAM 1.2 software (SAAM Institute, 
Seattle, WA) [66] to estimate its unknown parameters. Numerical values of the 
unknown parameters were estimated by using nonlinear least squares. Weights 
were chosen optimally, i.e., equal to the inverse of the variance of the 
Patients and Methods 
- 34 - 
measurement errors, which were assumed to be additive, uncorrelated, with zero 
mean, and a coefficient of variation (CV) of 6-8%. The unknown parameters of 
the model are: CPss, σ1, τ, σ2, θ, and δ. 
There are two main physiological outputs of the model: 
1. derivative control [pmol.m-2 BSA] . [mmol.l-1.min-1] -1: it is presented as the 
amount of insulin secreted in response to a rate of glucose increase of 1 
mmol/l per min which lasts for 1 minute;  
2. stimulus-response curve linking glucose concentration (x axis) to insulin 
secretion rate (ISR; y axis), when the derivative control is absent: as 
explained above, ISR is the sum of BSR and PSR, and it depends on the 
following three parameters estimated by the model: CPss, σ2, and θ. With 
the purpose of avoiding artifactual increases in the power of statistical 
analyses, we used the stimulus-response curve at the pre-selected glucose 
concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mM.  
 
Genotyping. 
A leukocyte DNA sample was collected for each patient and the DNA extraction 
was made through standard salting out method. Different genotyping methods 
have been used. All the DNA extraction and the genotyping have been performed 
at the Department of Mother and Child, Biology and Genetics – Section of 
Biology and Genetics – University of Verona, directed by Prof. Pinatti. 
 
RFLP-PCR (Restrinction Fragment Length Polymorphism – Polymerase 
Chain Reaction)  
The genomic DNA fragment containing the SNP of interest is amplified 
through PCR. The PCR product is then processed with a properly chosen 
restriction enzyme recognizing a specific binding site, including only one 
of the two allelic variants of the SNP. In this way it is possible to 
discriminate the genotype (Fig 6). 
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Fig. 6. RFLP. The restriction enzyme identified only one of the two allelelic variants of the SNP. 
In lane 3, 5 and 6 both the variants are present (heterozygous NM); in lane 8 only the allele not 
recognized by the enzyme is present and the PCR product is completely cut (homozygous NN); in 
lane 2 and 7 the enzyme did not identify its specific binding site and it did not cut (homozygous 
MM). On the Y axis the molecular weights references are reported.  
 
SNAPSHOT METHOD (ABI Prism Genetic Analyzer 310) 
This method is based on the single nucleotide primer extension technique 
and it allows to genotype up to 10 SNPs together. 
The genomic region bearing the SNP of interest is amplified through PCR 
followed by purification of the PCR product (see below steps 1-2). After 
that a mini-sequencing reaction is performed using fluorescent ddNTPs 
and a special primer, complementary to the region of the amplified DNA 
located just before the polymorphism (step 3). In this way only one single 
nucleotide, the one in correspondence to the SNP of interest, can be add to 
the primers. After another purification step, the reaction is loaded on a ABI 
Prism Genetic Analyzer 310 and a capillary electrophoresis is performed 
(Fig.7). The different alleles of the SNPs are characterized by a slightly 
different weight, which can be detected by the instrument. Moreover the 
probes have been designed of different length for the different 
contemporary analyzed polymorphisms in order to easily recognize them 
on the basis of the size of the fragment.  
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Herein is the protocol of the entire procedure: 
1. Amplify genomic DNA (tot 15 µl)  
2. Remove dNTPs and primers through SAP (5U) and ExoI (2U), 37°C 
1h and 72°C 15min 
3. Obtain purified template and quantify it 
4. Prepare sample reaction:  template (0,01-0,04 pmol) 
Primers (0,5-1 pmol) 
SNaPshot Multiplex (2X) 
 
 5.   Perform thermal cycling    
 
 
 
 
 
 
6. Remove unincorporated ddNTPs (SAP 1U) 
7. Samples electrophoresis on 310 ABI Prism SNaPshot Multiplex Kit 
8. Analyze data with GeneScan software  
 
 
Fig. 7. Electropherogram. Each polymorphism is represented by a single (homozygous) or a 
doubled peak (heterozygous) of different colours according to the nucleotide. 
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96°C 
10’’ 
50°C 
5’’ 
30’’ 
60°C 
4°C 
∞ 
Patients and Methods 
- 37 - 
TAQMAN. 
This method is the most commonly used for genotyping because it is 
reliable, reproducible and quick. 
A commercial assay is used for TaqMan genotyping and it contains both 
primers and fluorescent probes. There are two probes with two different 
fluorescent molecule, one for each alleles, at one side and a quencher at 
the other side for every SNP and they are complementary to the region 
surrounding the SNP, the polymorphism lays in the middle of the probe. 
According to the genotype of the SNP the probes could perfectly match or 
not. During the elongation phase the polymerase will find the probes on its 
way. If the probe perfectly matches, the enzyme will disrupt it, the 
fluorophore will be moved away from the quencher and it will emit 
fluorescence. However, if the matching is not perfect the whole probe will 
be moved away from the DNA strand but no fluorescence will be released. 
(fig.8). 
 
 
 
                Fig. 8  TaqMan genotyping principles. 
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Herein is the protocol of the procedure and the PCR programme. 
- 6-30 ng of genomic DNA  
- Master mix (Applied Biosystem) 2X 
- TaqMan Assay (Applied Biosystem) 40X 
- Water 
- Perform the following thermal cycling 
 
 
 
 
 
 
 
 
 
Statistical analysis. 
Data are presented as medians and interquartile range, unless otherwise indicated. 
Before performing statistical contrasts, skewed variables were log-transformed to 
improve the approximation to the Gaussian distribution and reported p-values are 
two-sided.  
The associations of TCF7L2 single variants with phenotypic traits have been 
explored by ANOVA generalized linear models (GLM) as implemented in SPSS. 
Since the logarithmic transformation was insufficient to improve the distribution 
of derivative control of beta-cell function, the latter was analyzed by Kruskal-
Wallis test. These statistical analyses were carried out with the software SPSS 
12.0. 
Haplotype association analysis was performed by generalized linear models 
(GLM) as implemented in the library haplo.stats [67] of the R package [68]. 
Associations between traits and haplotypes, allowing for ambiguous haplotypes, 
were investigated also by including relevant covariates such as age, gender and 
BMI. The statistical significance of global test and of single haplotype effects was 
ascertained by a Monte Carlo procedure in which the value of the trait was 
permuted among individuals and studied for association with the genetic factor in 
1000 replicates.11.0.  
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The associations between the genetic load and phenotypic traits were sought by 
generalized linear models (GLM) as implemented in SPSS. In each patient we 
calculated a genetic load score by summing up all the risk alleles of which he/she 
is a carrier. Patients were divided in 3 groups on the basis of this score: low (LGL: 
≤6, n=76), intermediate (IGL: 7-9, n=226) and high (HGL: ≥10, n=69) “genetic 
load” score. Parametric and nonparametric statistical methods were used as 
appropriate. Data were adjusted for age, gender and BMI if appropriate. Statistical 
significance was declared at p<0.05. 
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TCF7L2: RESULTS 
Clinical Features of the Study Population 
The clinical and metabolic features of the study sample are shown in table 3. They 
are referred to the population considered in the TCF7L2 study. Most patients were 
overweight or obese, but less than 50% were obese. However, abdominal obesity 
was present in 50% of males and in >75% of female patients. Glucose control, as 
measured by HbA1c, was fairly good with only 25% patients with HbA1c>7.4%. 
High triglycerides and low HDL-cholesterol were common, especially the latter 
one in the female patients. Systolic and diastolic hypertensive values were 
detected in 50% and 25% of the patients, respectively.   
 
Variable Males Females All 
Number  315 149 464 
Age (yrs) 59 [51-65] 61 [53.5-66.5] 59 [52-65] 
BMI (kg/m2) 28.8 [26.2-32.3] 30 [27.1-34.3] 29.3 [26.5-32.9] 
Waist (cm) 102 [95-11.7] 97 [90-104] 100 [94-109] 
Fasting P-glucose (mmol/l) 7 [6.1-8] 7.2 [6.1-8] 7 [6.1-8] 
2-h P-glucose (mmol/l) 13.3 [10.6-16.2] 12.8 [10.2-16.1] 13.3 [10.5-16.2] 
HbA1c (%) 6.7 [6.1-7.5] 6.7 [6.2-7.4] 6.7 [6.1-7.4] 
Triglycerides (mmol/l) 1.4 [1-2] 1.3 [1-2] 1.4 [1-2] 
HDL-cholesterol (mmol/l) 1.1 [0.9-1.3] 1.2 [1-1.4] 1.1 [1-1.3] 
Total Cholesterol (mmol/l) 4.9 [4.3-5.6] 5.2 [4.5-5.8] 5 [4.3-5.7] 
SBP (mmHg) 134 [124-150] 140 [130-150] 139 [125-150] 
DBP (mmHg) 85 [80-90] 85 [80-90] 85 [80-90] 
Insulin Sensitivity (µmol/min/m2 BSA) 572 [317-819] 536 [396-754.5] 562 [356-790] 
Insulinogenic Index (mU/mmol) 3.4 [2.0-5.9] 4.3 [2.3-7.5] 3.5 [2.0-6.1] 
CIR120’ (mUxL/mmol2) 0.4 [0.2-1.1] 0.7 [0.2 – 1.4] 0.5 [0.2-1.2] 
Table 3. Clinical characterization of TCF7L2 study population. The values are reported as median 
[interquartile range]. 
 
Effects of the risk alleles of TCF7L2 
We analyzed 4 SNPs in TCF7L2: rs7901965T/C and rs7903146C/T (intron 3), 
rs11196205G/C and rs12255372G/T (intron 4) (the second allele is the risk 
allele). The genotype frequencies for all 4 SNPs were in Hardy-Weinberg 
equilibrium and their frequencies are reported in table 4. The location of the 4 
SNPs and the linkage disequilibrium block they form are shown in fig. 9. The 4 
adjacent SNPs are in strong LD (D’=0.91;0.88;0.87).  
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Fig. 9 SNPs location and LD plot elaborated with Haploview. LD values are reported as D’. 
 
  TCF7L2 
SNP rs7901695 rs7903146 rs11196205 rs12255372 
GENOTYPE TT TC CC CC CT TT GG GC CC GG GT TT 
NUMBER 144 234 86 146 233 85 108 226 129 167 225 72 
RISK 
ALLELE 
FREQUENCY 
0,44 0,43 0,52 0,39 
Table 4  Risk allele frequencies are reported for each SNP, the orange allele is the risk one. 
 
The clinical characteristics of the study population stratified according to 
rs7901695, rs7903146, rs1196205 and rs1225372 are shown in tables A to D in 
the Appendix.  
The diabetes risk alleles of rs7901695, rs7903146 and rs12255372 were 
associated to lower BMI, but only when analyzed under the hypothesis of a 
dominant model (Appendix, tables A, B and D). The risk alleles of rs7901695, 
rs7903146 and rs11196205 were associated to higher fasting plasma glucose, but 
not to 2-hour plasma glucose during the OGTT or to HbA1c (Appendix, tables A, 
B and C). The risk allele of rs7903146 was associated with lower triglycerides 
(Appendix, table B). This association was still significant after adjusting for age, 
gender and BMI, but not after adjusting for fasting insulin. 
None of the four TCF7L2 variants influenced insulin sensitivity, as measured by 
the euglycemic insulin clamp (Appendix, tables A, B, C and D). 
Neither the insulinogenic index nor CIR120 were significantly changed in the 
carriers of any risk allele (Appendix, tables A, B, C and D), although trends for 
reduction were observed for all 4 SNPs. 
State-of-art analysis of beta-cell function showed a different pattern. The 
derivative control of beta-cell function showed no significant changes in the 
presence of the risk alleles of TCF7L2 (Table 5). However, the stimulus-response 
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curve relating plasma glucose concentration to insulin secretion rate, after 
correcting for age, gender and BMI, showed a significant, graded downward shift 
in the carriers of the risk alleles (fig. 10) of both rs7901695 and rs7903146, but 
not of rs1196205 or rs1225372. 
 
  n Risk allele 
frequency 
Not risk allele 1 risk allele 2 risk alleles P Value 
rs7901695  464  0.44 525 [2-921] 376 [0.6-954] 530 [219-888] 0.38 
rs7903146  464  0.43 525 [0.5-939] 382 [0.2-957] 528 [227-873] 0.46 
rs11196205  464  0.52 423 [0-1031] 388 [0.5-893] 523 [166-913] 0.36 
rs12255372  464  0.39 529 [56-921] 376 [0-935] 572 [257-906] 0.15 
 
Table 5 Derivative control of beta-cell function in patients of the Verona NDDS according to 
genotype of TCF7L2 variants. Data are presented as median [I.Q. Range]; units are pmol.m-2.BSA 
per.min-1 
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Fig. 10 The proportional control of β-cell function decreases at the increasing number of 
rs7901695 risk alleles. The same result is obtained for rs7903146. 
 
p=0.019 
p=0.022 
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Effects of TCF7L2 Haplotypes 
Haplotype analysis showed that 4 main haplotypes could be detected in our study 
population. They were denominated arbitrarily after their approximate percent 
frequency. Additional rare (frequency<3%) haplotypes were grouped together and 
accounted for ~7% of the total number of haplotypes (table 6). 
Two haplotypes, haplo.46 and haplo.35, accounted for 80% of all haplotypes. 
Haplo.46 was formed by all nonrisk alleles, whereas haplo.35 was composed by 
all risk alleles. Haplo.35 had higher fasting plasma glucose (table 11). 
Furthermore, haplo.35 was associated to a lower curve relating plasma glucose 
concentration to insulin secretion rate at all glucose levels (p<0.01 or less) (fig. 3). 
Also haplo.9 and haplo.4 showed an interesting pattern. Haplo.9 was associated 
with the best beta-cell function compared to the other haplotypes, as manifested 
by an upward shift in the stimulus-response curve relating plasma glucose to 
insulin secretion rate (fig. 11). At the highest glucose concentration (20 mM) 
haplotype 9 was associated with ~25% higher insulin secretion rate than the two 
most prevalent haplotypes. Haplo.4 was associated with higher fasting plasma 
glucose (table 7) and with the worst beta-cell function compared to the other 
haplotypes, as manifested by a downward shift in the stimulus-response curve 
relating plasma glucose to insulin secretion rate (fig. 11). At the highest glucose 
concentration (20 mM) Haplo.4 was associated with ~30% lower insulin secretion 
rate than the two most prevalent haplotypes. The effect of Haplo.4 on beta cell 
function was no longer significant after correcting for fasting plasma glucose. The 
p-values related to the stimulus-response curves (Fig.11) are reported in table 8. 
Of the insulin-derived indexes of beta-cell function, CIR120’, but not the 
insulinogenic index, was significantly related to TCF7L2 haplotypes (table 7), 
with Haplo.9 showing the best response and Haplo.4 the worst response. No other 
haplotype associated effects were detected in any other tested phenotype. 
Haplotypes: 
  rs7901695 rs7903146 rs11196205 rs12255372 hap.freq 
haplo.4         C T C G 0,0383 
haplo.36         C T C T 0,3479 
haplo.9         T C C G 0,0864 
haplo.rare      * * * * 0,0715 
haplo.45      T C G G 0,4559 
 
Table 6 Haplotype composition and distribution in the studied population. 
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 N Mean value ± SEM Coefficients ± SEM P-Value 
Variable  Haplo.45 (reference) Haplo.36 Haplo.9 Haplo.4  
Frequency (%) 
 44.8 36.1 8.6 3.7  
Age (yrs) 460 56.9 ± 0.89 +1.31 ± 0.76 +0.69 ± 1.3 +0.67 ± 1.9 0.5 
BMI (kg/m2) 460 30.26 ± 0.44 -0.39 ± 0.38 +0.32 ± 0.65 -0.89 ±  0.95 0.43 
Waist (cm) 451 101.99 ± 1.07 -1.2 ± 0.92 +0.32 ± 1.57 -0.62 ± 2.27 0.33 
Fasting P-glucose (mmol/l) 459 6.98 ± 0.15 +0.33 ± 0.13 +0.05 ± 0.22 +0.57 ± 0.32 0.03 
2-h P-glucose (mmol/l) 459 13.45 ± 0.35 +0.3 ± 0.3 -0.13 ± 0.5 +1.3 ± 0.75 0.12 
HbA1c (%) 453 6.97 ± 0.11 +0.05 ± 0.09 +0.04 ± 0.16 -0.02 ± 0.24 0.68 
Triglycerides (mmol/l) 457 1.64 ± 0.09 -0.05 ± 0.082 +0.13 ± 0.14 +0.1 ± 0.23 0.3 
HDL-cholesterol (mmol/l) 454 1.19 ± 0.03 +0.02 ± 0.027 -0.08 ± 0.046 +0.05 ± 0.068 0.15 
Total Cholesterol (mmol/l) 457 5.04 ± 0.08 -0.05 ± 0.07 -0.02 ± 0.12 -0.23 ± 0.18 0.38 
SBP (mmHg) 452 139.03 ± 1.6 -2.01 ± 1.43 +0.84 ± 2.4 -1.44 ± 3.47 0.6 
DBP (mmHg) 452 85.08 ± 0.85 -0.4 ± 9.73 +0.03 ± 1.23 -0.6 ± 1.79 0.96 
Insulin Sensitivity 
(µmol/min/m2 BSA) 452 609 ± 26.9 +19.8 ± 24.9 -53.3 ± 44.2 -13.5 ± 13.2 0.7 
Insulinogenic Index 
(mU/mmol) 411 4.84 ± 0.79 +0.15 ± 0.68 +1.1 ± 1.1 -0.13 ± 1.5 0.23 
CIR120’ (mUxL/mmol2) 427 0.89 ± 0.097 -0.05 ± 0.082 +0.24 ± 0.14 -0.30 ± 0.19 0.045 
Derivative Control 
[(pmol/m2BSA)/(mM/min)] 460 585 ± 17.53 +9.5 ± 18.18 +103 ± 2.88 -84.1 ± 1.11 0.16 
 
Table 7. Effects of TCF7L2 haplotypes on clinical and metabolic features of the Verona NDDS 
population. Data are presented as mean±SEM for the reference haplotype, while for the other  
haplotype coefficients ±  SEM are reported. 
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Fig. 11 Proportional control of the β-cell function is represented as the stimulus-response curve, 
with insulin secretion rate (ISR) on the Y axis and glucose concentration on the X axis. Haplo.4 is 
associated with a decreased ISR, while Haplo.9 shows increased ISR, both in comparison with the 
reference haplotype, Haplo.45.  
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Table 8 The overall p-value refers to any haplotype influence on the different levels of the 
stimulus-response curve. The other p-values refer to individual haplotype related differences in the 
stimulus-response curve when compared to Haplo.45 (reference haplotype).  
 
 
 
HAPLOTYPES 
HAPLO.45 HAPLO.36 HAPLO.9 HAPLO.4 Glycaemia (mmol/l) 
mean sem Coef sem p-value coef sem p-value Coef sem p-value 
Overall 
p-vaue 
5,5 86,83 5,76 -15,85 4,91 0,001 -5,25 8,5 0,5 -21,4 12,4 0,08 0,009 
8 120,76 9,6 -25,36 8,17 0,001 -0,3 14,2 0,9 -49,9 20,4 0,015 0,003 
11 190,75 13,8 -36 15,2 0,009 32 23,8 0,17 -90,7 37.9 0,02 0,005 
15 299,65 26,2 -45,6 26,4 0,003 57,5 46,5 0,03 -152,1 67,2 5*10-4 0,021 
20 439,8 41,8 -60,8 43,3 <10-4 83,9 74,4 0,0014 -203,7 106 <10-4 0,064 
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TCF7L2: DISCUSSION 
In this study we assessed the associations of 4 variants in TCF7L2, investigated as 
single SNPs as well as specific haplotypes, with main clinical and 
pathophysiological features in patients with newly diagnosed T2DM. TCF7L2 
variants still represent the strongest genetic signal associated to an increased risk 
of T2DM and they may play a causal role through several mechanisms, including 
decreased beta-cell mass, impaired insulin processing or release, impaired GLP-1 
signalling in beta cells, abnormal glucagon secretion, liver insulin resistance and 
altered chromatin state in T carriers. 
Novelties of the present study are: 1. it was carried out in patients with newly 
diagnosed T2DM; 2. it applied state-of-the art methods to assess the two main 
physiological traits responsible for glucose homeostasis, i.e. beta-cell function and 
insulin sensitivity; 3. it explored the association of TCF7L2 haplotypes with main 
clinical and pathophysiological phenotypes.  
We observed that risk alleles of 3 out of 4 TCF7L2 SNPs were associated with 
significantly lower BMI and significantly higher fasting plasma glucose, although 
it should be noted that the SNP triplet was not the same in the two cases. The first 
finding is somewhat reminiscent of an earlier study [69] in which a risk haplotype 
of TCF7L2 was associated with lower BMI in patients with T2DM, and it may 
imply that the genetic risk conferred by TCF7L2 leads to overt diabetes for lower 
BMI thresholds, all other clinical features being equal. Higher fasting plasma 
glucose in our study was not accompanied by higher 2-hour plasma glucose or 
HbA1c. Thus, it does not reflect poorer glucose control, but, perhaps, it may be 
related to some TCF7L2 related pathogenetic mechanisms with a particularly 
relevant impact on fasting glucose (see below). 
Only the risk allele of rs7903146 showed a significant association with lower 
triglyceride levels (Appendix, table B). Beyond the possibility of being only a 
finding due to the chance, it should be noted that the association between 
rs7903146 and triglyceride levels was lost after adjusting for fasting insulin levels, 
thus suggesting that it is probably mediated by the latter. Indeed, it is well known 
that hyperinsulinemia is an important co-determinant of hypertriglyceridemia. The 
most likely interpretation, therefore, is that rs7903146 risk allele exerts an effect 
on triglyceride levels through its effect on beta-cell function (see below). Further 
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support to this interpretation comes form recent data obtained in individuals 
belonging to families with familial combined hyperlipidemia [70] and in 
European Americans of the Genetics of Lipid Lowering Drugs and Diet Network 
Study [71] In both cases, the risk allele of rs7903146 was found related to high 
triglycerides and VLDL levels. 
In this study, the risk alleles of rs7901695 and rs7903146 were associated with 
reduced beta-cell function, as assessed by state-of-the art techniques (Fig. 10). 
Interestingly, these risk alleles are associated with reduced beta-cell function not 
only in nondiabetic individuals, as previously reported, but also in patients with 
newly diagnosed T2DM. In nondiabetic individuals the association between 
TCF7L2 variants and beta-cell function is used to explain the higher risk of 
T2DM in subjects with these variants. Our findings that the same allelic variants 
are associated with a poorer beta-cell function also in newly diagnosed T2DM 
subjects strongly support the conclusion that TCF7L2 plays a major role in the 
development of diabetes and in contributing to the leading physiologic 
abnormality of the disease, i.e. beta-cell dysfunction.  
Recent evidence indicates that in nondiabetic individuals the risk allele of 
rs7903146 marks insulin resistance in the liver, as manifested by an increased 
endogenous glucose output both in the postabsorptive state and during a 
euglycemic insulinemic clamp (performed at the same insulin dose employed in 
our study). We herein report no effect of rs7903146, or other SNPs, on insulin 
sensitivity as assessed by the euglycemic insulinemic clamp. However, the risk 
alleles of 3 TCF7L2 SNPs, including rs7903146, were associated with higher 
fasting plasma glucose, a major determinant of which is endogenous glucose 
output and its sensitivity to insulin. Furthermore, in our study we did not measure 
liver but rather whole body insulin sensitivity, i.e. the algebraic sum of liver and 
peripheral insulin sensitivities. In the very same study which reported liver insulin 
resistance in rs7903146T carriers, whole body insulin sensitivity was slightly, 
albeit non significantly, increased, not decreased, in rs7903146T carriers. Thus, 
our data are not inconsistent with Pilgaard’s findings [37, 40, 46, 49] 
Previous studies have endeavoured to investigate the role played by TCF7L2 
haplotypes in determining clinical and metabolic phenotypes. Helgason et al 
reported that the haplotype HapBT2D, which includes rs7903146T, was associated 
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with lower BMI in subjects with T2DM [69]. In another study, 11 tag SNPs in 
TCF7L2 were genotyped [72] and 15 haplotypes (frequency from 0.12 to 40%) 
were identified by using four diabetes risk SNPs. Haplotype hap2 (frequency 
26%), which lacks the risk alleles for all four SNPs, was associated with a strong 
protection against T2DM, higher age of onset of the disease and lower 2-h glucose 
values. 
To the best of our knowledge, our study is the first in which TCF7L2 haplotypes 
are assessed together with state-of-the-art assessment of beta-cell function and 
insulin sensitivity. In our study, several TCF7L2 haplotypes had low frequency 
(i.e. <3%), accounted altogether for 7% of all haplotypes, and will not be 
discussed further. Two haplotypes together reached a frequency of ~80%. One of 
them (frequency ~35%) was formed only by the diabetes risk alleles of the 4 
SNPs. The other (frequency ~46%) was formed only by non-risk alleles of the 4 
SNPs. Accordingly, the latter was associated to a statistically significant 14-21% 
reduction in the stimulus-response curve relating glucose concentration to insulin 
secretion (Fig. 11). These findings seem to support the view that, as to TCF7L2, 
the pathophysiologic counterpart of at-risk variants is beta-cell function. 
The other two haplotypes display a frequency of about 9% and 4%. The former is 
associated with better, the latter with poorer beta-cell function than the two most 
prevalent haplotypes. Again, the effect of TCF7L2 genetic variants was selective 
for the stimulus-response curve linking glucose concentration to insulin secretion 
rate. The derivative control of beta-cell function was unaffected (table 5). 
The size of the haplotype effect on beta-cell function was relevant: Haplo.9, the 
“good haplotype”, had almost twice higher beta-cell response to glucose than 
Haplo.4, the “bad haplotype”. This difference may be of clinical relevance from 
the diagnostic, prognostic and therapeutic viewpoints. Furthermore, both 
haplotypes might deserve to be considered when assessing beta-cell function and 
T2DM risk in nondiabetic individuals. To the extent that beta-cell function is a 
phenotypic marker of genetically-determined diabetes risk, the “bad haplotype” 
might be one of those low-frequency genetic risk regions with large size impact 
on diabetes risk which are currently searched in order to expand our knowledge 
on the genetic basis of T2DM. Conversely, the “good haplotype” might be used to 
identify those who are protected against T2DM.  
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It is noteworthy that the roles exerted by TCF7L2 variants and haplotypes on beta-
cell function may hint that through the genotype one might capture a sizeable 
fraction of the variability in beta-cell function of the patient with newly diagnosed 
T2DM. This possibility deserves to be explored thoroughly in the future.  
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GENETIC LOAD: RESULTS 
The clinical features of subjects included in the GENETIC LOAD study are very 
similar to the TCF7L2 study. They are reported in table 9. 
 
Variable Males Females All 
Number  248 123 371 
Age (yrs) 58 [51-64] 61 [54-67] 59 [52-65] 
BMI (kg/m2) 28.9 [26.1-32] 30 [27.2-34] 29.2 [26.4-32.6] 
Waist (cm) 102 [95-110] 97 [90-104] 100 [93-108] 
Fasting P-glucose (mmol/l) 7 [6.1-7.9] 7.1 [6.1-8.3] 7.1 [6.1-8] 
2-h P-glucose (mmol/l) 13.3 [10.9-16.2] 13.1 [10.3-16.4] 13.3 [10.7-16.3] 
HbA1c (%) 6.7 [6.2-7.5] 6.8 [6.1-7.4] 6.7 [6.1-7.5] 
Triglycerides (mmol/l) 1.4 [1-2] 1.4 [1-2] 1.4 [1-2] 
HDL-cholesterol (mmol/l) 1.1 [1-1.3] 1.2 [1-1.4] 1.1 [1-1.4] 
Total Cholesterol (mmol/l) 4.9 [4.3-5.5] 5.3 [4.4-5.8] 5 [4.3-5.6] 
SBP (mmHg) 140 [128-150] 140 [130-150] 140 [128-150] 
DBP (mmHg) 85 [80-90] 86 [80-90] 85 [80-90] 
Insulin Sensitivity (µmol/min/m2 BSA) 578 [318-821] 535 [387-768] 565 [352-796] 
Insulinogenic Index (mU/mmol) 3.3 [1.9-5.9] 4.3 [2.1-6.9] 3.7 [2-6.2] 
CIR120’ (mUxL/mmol2) 0.4 [0.2-1] 0.6 [0.2-1.3] 0.5 [0.2-1.1] 
Table 9 Clinical features of the genetic load study population. The values are reported as median 
[interquartile range]. 
 
In this study we aimed to assess the joint effect of 8 T2DM associated 
polymorphisms in determining clinical and pathophysiological traits of interest. 
The 8 analyzed SNPs are listed in table 2 and 10.  
Preliminary to this analysis was the assessment of the effects exerted by each 
single variant, but none of them reached statistical significance individually, either 
for clinical and pathophysiological parameters (data not shown).  
We then carried on assessing the joint effect of these SNPs (“genetic load”) on 
key metabolic phenotypes, i.e. beta-cell function and insulin sensitivity, and also 
on clinical features. We gave different values to the alleles for each SNP: 0 to the 
not-risk allele and 1 to the risk allele. In this way we were able to calculate a sort 
of “genetic score”, summing up all the risk alleles values for each patients. Since 
we considered 8 SNPs, the genetic load score potentially ranges between 0 
(patients with no risk alleles) and 16 (patients homozygous for risk alleles in all 
SNPs). We then divided the studied population into three groups on the basis of 
the number of risk alleles: Low (LGL: ≤6, n=76), Intermediate (IGL: 7-9, n=226) 
and High (HGL: ≥10, n=69) “Genetic Load” score. Table 10 lists the SNPs under 
study, related genes, risk alleles and frequency.  
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SNP Nearest gene Not-risk/risk alleles MAF 
rs679931 CACNA1E A/T 0.37 
rs1801282 PPARG T/C 0.07 
rs1044498 ENPP1 A/C 0.16 
rs10946398 CDKAKL1 A/C 0.30 
rs1111875 HHEX G/A 0.38 
rs10010131 WFS1 A/G 0.35 
rs4430796 TCF2 A/G 0.43 
rs4402960 IGF2BP2 G/T 0.35 
 
Table 10. Genotyped SNPs and alleles frequencies are reported. The minor allele is underlined, in 
orange the risk one. MAF: Minor Allele Frequency. CACNA1E: Calcium channel, voltage-dependent, 
R type, alpha 1E subunit; PPARG: Peroxisome proliferator-activated receptor-gamma; ENPP1: 
Ectonucleotide pyrophosphatase/phosphodiesterase 1; CDKAL1: CDK5 regulatory subunit-
associated protein1-like1; HHEX: Haematopoietically expressed homeobox; WFS1: Wolfram syndrome 
1; TCF2: Transcription factor 2; IGF2BP2: Insulin-like growth factor 2 mRNA binding protein 2 
Effects of genetic load on clinical and phatophysiological T2DM phenotypes. 
In table 11 the clinical features of the three groups (low, intermediate and high 
genetic load score) are reported. No significant differences were detected among 
the three groups, although a trend of the insulinogenic index to decrease with 
increasing genetic load scores was noticed. Similarly, no differences were 
detected in the derivative control of beta-cell function (table 12). However, the 
stimulus-response curve relating glucose to insulin secretion rate (proportional 
control) showed a statistically significant graded reduction with higher genetic 
load scores (fig. 12).  
Variable Genetic Load Score p-value 
 LGL IGL HGL  
Number 76 226 69  
Age (yrs) 57,8±10,8 58.2±9.6 57.2±10.7 0.8 
BMI (kg/m2) 30.1±5.5 30.3±5.1 28.4±3.8 0.07 
Waist (cm) 101.2±12.6 102.2±12.3 98.9±11.1 0.1 
Fasting P-glucose (mmol/l) 7.2±1,4 7.2±1.9 7.4±1.7 0.6 
2-h P-glucose (mmol/l) 12. 8±4 13.6±4 14.3±4.1 0.09 
HbA1c (%) 6,8±1,1 7±1.2 7±1.1 0.4 
Triglycerides (mmol/l) 1.6±0.7 1.6±1.1 1.8±1.4 0.4 
HDL-cholesterol (mmol/l) 1.1±0.3 1.2±0.3 1.2±0.5 0.8 
Total Cholesterol (mmol/l) 5±0.9 5±1 5.2±0.9 0.3 
SBP (mmHg) 138.7±17.9 139±18.6 138.3±17.6 0.9 
DBP (mmHg) 83.6±9 85.9±9.1 84.5±10.1 0.2 
Insulin Sensitivity 
(µmol/min/m2 BSA) 634±373 597±318 634±383 0.6 
Insulinogenic Index 
(mU/mmol) 5.6±5 5±4.6 4.2±4.1 0.2 
CIR120’ (mUxL/mmol2) 1±1.2 0.8±1 0.7±0.7 0.2 
Table 11 Clinical and phatophysiological features stratified by the genetic load score are reported 
in this table as mean±DS. There are no statistically significant differences among the three groups. 
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 N Median [range IQ] P Value 
LGL 76 432 [0-911] 
IGL 226 420 [71-888] 
HGL 69 330 [0-780] 
0.8 
 
Table 12. Derivative control of beta-cell function in patients of the Verona NDDS according to the 
genetic load score groups. Data are presented as median [I.Q. Range]; units are pmol.m-2.BSA per 
mM.min-1 
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Fig. 12. The proportional control of beta-cell function is plotted as the stimulus-response curve, 
with insulin secretion rate (ISR) on the Y axis and glucose concentration on the X axis. In this 
analysis the higher is the genetic load score the lower the response of beta-cell to plasma glucose. 
 
p=0.05 
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GENETIC LOAD: DISCUSSION 
In type 2 diabetes. each of the recently discovered risk loci per se contributes 
quantitatively little to the overall risk. Not surprisingly, they are often of 
questionable biological significance in affecting beta-cell function and insulin 
sensitivity. To the present day the highest odd ratio is attributable to the TCF7L2 
variant rs7903146 (OR~1.4). 
Since T2DM is a complex disease, multiple genetic factors are involved in its 
development. For this reason we tried to assess the joint effect of different risk 
alleles in our patients with newly-diagnosed T2DM. 
We chose 8 loci already seen to be associated with increasing risk of T2DM. We 
deliberately did not include TCF7L2 variants, to be sure that the effect, if any, is 
not depending on this strong diabetogene at all.  
We found no differences among the three genetic load score groups for any of the 
standard clinical features, including indexes of obesity and of glucose control.  
A trend for a worse insulinogenic index with higher genetic load score was not 
statistically significant. However, the proportional control of beta-cell function 
showed a graded worsening moving from the low to the intermediate to the high 
genetic load score group.  
Many other research groups have previously investigated the combined effect of 
different risk alleles, but they all mainly analyzed the genetic load in relation to 
the risk of T2DM. 
The first two studies that used this kind of combined analysis were carried out 
before the identification of the new T2DM associated polymorphisms, so they 
considered just 2 or 3 SNPs (PPARG, KCNJ11 and TCF7L2) [51, 73]. They both 
found that each additional risk allele increases the risk of T2DM in an additive 
manner. They tested also the interaction among the different variants but they 
found no evidence of it. 
Even though these two studies were conducted in a small number of gene variants, 
the overall risk could be considered as the sum of the effects of each SNP. 
After the development of the GWAS, a number of studies considering the 
combined effect of several T2DM associated polymorphisms have been published 
[50, 52-54, 74]. They all mainly analyzed the risk of type 2 diabetes and 
concluded that the higher is the number of risk alleles the higher is the risk of 
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developing the disease, but they came to different conclusions regarding the 
usefulness of genetic factors in improving the ROC (Receiver Operating 
Characteristic) curve of disease prediction. This curve indicates how useful 
adding further risk factors could be in predicting risk of future diabetes. Adding 
the genetic data to clinical risk factors, Cauchi et al. [52] found an improvement in 
the prediction of the disease, while other groups [53, 54] found that genetic 
factors improved very little the capacity of clinical parameters to predict T2DM. 
These different results could reflect different strategies in selecting the study 
samples: a case control study in the French paper [52] and population-based 
studies in the ones by Meigs and Lyssenko [53, 54]. 
In our study we did not consider the ROC curve of disease prediction, because our 
study sample was formed by patients with diabetes. We instead focused on the 
influence of the genetic load score on the pathophysiological parameters. In the 
Swedish group paper [53] also this aspect was considered and they found that in 
nondiabetic subjects a higher number of risk alleles is associated with worse beta-
cell function, measured as Disposition Index and insulin secretion. This result is 
comparable with the decreased proportional control that we found in our 
population, even though the methods of assessment of the beta-cell function are 
different. 
Two recently published papers focused on the cumulative effect of several T2DM 
associated polymorphisms on beta-cell function [47, 75] and both of them 
concluded that the higher is the number of risk alleles, the worse is the beta-cell 
function. 
These two studies are similar to ours for several reasons: - pathophysiological 
traits of T2DM and not the risk for the disease have been studied; - they are 
neither a case control nor a population based study; - they analyzed only non-
diabetic subjects, whereas we studied newly-diagnosed diabetic patients; - all 
three studies found an association between the genetic load score and beta-cell 
function. 
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CONCLUSIONS 
The novelty of this study is rooted in the accurate characterization, with state-of-
art methods, of typically the two main pathophysiological traits characterizing 
type 2 diabetes: beta-cell function and insulin sensitivity.  
Commonly used indexes of insulin secretion were not significantly associated to 
TCF7L2 variants (Appendix tables from A to D). This points out that these 
surrogate indexes are less sensitive than parameters generated by state-of-the art 
techniques. Indeed, both insulinogenic index and CIR120’ encompass several 
physiological facets of the insulin system, some of which, e.g. insulin clearance, 
are not related to beta-cell secretory function. Furthermore, only the stimulus-
response curve between glucose concentration and insulin secretion rate was 
found to be selectively impaired by TCF7L2 genetic variants (fig. 10), whereas no 
changes in the derivative control were observed (table 5). 
Similar conclusions can be drawn for the GENETIC LOAD study. Also in this 
case the surrogate indexes disclosed no associations with genetic factors, but the 
analysis of proportional control of beta-cell function highlighted a reduction in 
beta-cell function in subjects with a greater number of risk alleles. 
Our study has a number of limitations. First, the Verona NDDS is not a population 
based study, although subjects in the cohort are fairly representative of Italian 
patients with T2DM. Nonetheless, the Verona NDDS cohort has a somewhat 
higher than expected prevalence of males, possibly reflecting a gender related 
referral bias. Second, although we used state-of-the art methods to assess beta-cell 
function and insulin sensitivity, many relevant pathophysiological facets were 
unexplored, e.g. incretin axis and liver vs. peripheral insulin resistance. Third, our 
study was performed in Italian patients and transferability of our results to other 
ethnic groups should be made with caution. Fourth, subjects with severe glycemic 
decompensation were excluded for ethical reasons and this might have biased our 
findings. Finally, as in all association studies and particularly for the TCF7L2 
study, our findings need to be replicated.  
In summary, we have reported evidence that genetic variants of TCF7L2, both at 
the single SNP and at the haplotype level, may play a significant role in 
determining beta-cell function in patients with newly diagnosed T2DM. Two low 
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frequency TCF7L2 haplotypes that we have identified may deserve to be further 
investigated, also in nondiabetic individuals. 
Regarding the GENETIC LOAD study, its results emphasize the value of 
investigating the combined effect of several T2DM associated polymorphisms. 
Indeed, even though many studies have shown that the genetic load has a 
measurable impact on T2DM risk, our findings suggest that it could have an 
important role in determining clinical and pathophysiological phenotypes in 
diabetic patients.  
Genetics of type 2 diabetes is a continuously evolving field. Most recent papers 
have identified novel additional loci associated to T2DM, only some of which 
with known function, such as KCNQ1 (Potassium Channel, Voltage-Gated, KQT-
like subfamily, member 1) [27, 28] and MNTR1B (Melaton Receptor 1B) [29-31]. 
For most of the T2DM risk loci, biological function and role in the disease are still 
unknown. Many further studies will be necessary to elucidate the role of genetics 
in this disease.  
We propose that our findings support the conclusion that, in order to define 
metabolic phenotypes and, perhaps, personalized treatment and prognosis of 
T2DM, genotyping might be a simpler and cheaper approach than using the gold-
standard techniques of clinical physiology. 
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APPENDIX 
 
Table A. Influence of Rs7901695 genotype on clinical and metabolic variables of patients with newly 
diagnosed type 2 diabetes in the Verona NDDS. *Variables were log-transformed before statistical 
analysis to approximate a gaussian distribution; the coefficient beta and its S.E. refer to log-transformed 
values. § p-value still significant after adjustment for age, sex and BMI. 
 
 rs7901695 Additive mode (Dominant model) 
Phenotype Number TT TC CC BETA SE P  Value 
Risk (A) allele frequency, % 0.44 
   
Number (M/F) 464 (315/149) 144 234 86    
Age (yrs) 464 59 [52.2-65] 59 [51-65] 61 [51.7-67] 0.76 0.67 0.258 
BMI* §(kg/m2) 464 30.4 [27.3-33.5] 
28.7 [26.2-
32.5] 
28.4 [26.2-
32.2] -0.03 0.01 (0.047) 
Fasting P-glucose § 
(mmol/l) 463 6.8 [6.1-7.7] 7.2 [6.1-7.9] 7.4 [6.1-8.6] 0.3 0.11 0.009 
2hr P-glucose (mmol/l) 463 13.3 [10.7-16.1] 
12.7 [10.1-
16.2] 
14.3 [10.8-
16.9] 0.33 0.28 0.22 
Fasting insulin* (mU/l)  459 
12.1 [7.5-
17.2] 
11.5 [7.7-
16.9] 
9.8 [6.9-
13.7] -0.06 0.04 0.11 
2hr insulin* (mU/l) 426 74.3 [43-105.9] 
61 [40.4-
95.1] 
58.7 [30.7-
104.7] -0.09 0.05 0.07 
Insulinogenic Index* 
(mU/mmol) 411 4.2[2.1-6.3] 3.7 [2-6.8] 3.5 [1.8-5.7] -0.09 0.07 0.19 
CIR120’*(mUxL/mmol2) 425 0.5 [0.2 –1.2] 0.5 [0.2-1.3] 0.4 [0.2-0.9] -0.11 0.08 0.18 
HbA1c 453 6.7 [6.1-7.5] 6.7 [6.1-7.4] 6.7 [6.1-7.6] 0.06 0.09 0.47 
Triglycerides * (mmol/l) 456 1.4 [1-2] 1.4 [1.1-2.1] 1.4 [0.9-1.8] -0.05 0.03 0.16 
HDL-cholesterol 
(mmol/l) 452 1.1 [1-1.4] 1.1 [1-1.3] 1.2 [1-1.4] 0.015 0.02 0.5 
Cholesterol (mmol/l) 455 5.1 [4.2-5.7] 5 [4.4-5.7] 4.8 [4.4-5.5] -0.05 0.07 0.5 
SBP (mmHg) 448 140 [130-150] 138 [124-150] 
134 [120-
150] -1.7 1.2 0.17 
DBP (mmHg) 448 85 [80-90] 85 [80-90] 84 [80-90] -0.2 0.65 0.7 
Insulin Sensitivity* 
(µmol/min/m2 BSA) 449 
577 [317-
753]] 
553 [366-
840] 
585.5 [387-
819] 0.06 0.04 0.17 
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 rs7903146 Additive model  (Dominant model) 
Phenotype Number CC CT TT BETA SE P  Value 
Risk (T) allele frequency, % 0.43 
   
Number (M/F) 464 (315/149) 146 233 85    
Age (yrs) 464 59 [52-65] 59[52-65] 60[50-67] 0.5 0.7 0.44 
BMI* § (kg/m2) 464 30.5 [27.4-33.5] 
28.7 [26.3-
32.5] 
28.3 [26.0-
32.9] -0.01  0.01 (0.036) 
Fasting P-glucose § 
(mmol/l) 463 6.8 [5.9-7.7] 7.2[6.1-8] 7.3 [6.2-8.6] 0.25 0.11 0.027 
2hr P-glucose 
(mmol/l) 463 
13.3 [10.6-
16.1] 
12.8 [10.2-
16.3] 
14.0 [10.6-
16.6] 0.22 0.28 0.41 
Fasting insulin* 
(mU/l) 459 
12.2 [7.5-
17.4] 
11.5 [7.8-
16.8] 9.6 [6.9-13.8] -0.07 0.04 0.085 
2hr insulin* (mU/l) 426 74.1 [43.8-106.3] 
60.0 [40.3-
94.7] 
61.7 [31.2-
107.9] -0.09 0.05 0.09 
Insulinogenic Index* 
(mU/mmol) 411 4.0 [2.0-6.2] 3.5 [2.0-6.3] 3.3 [1.6-5.2] -0.097 0.07 0.15 
CIR120’ * 
(mUxL/mmol2) 425 0.5 [0.2-1.3] 0.5 [0.2-1.3] 0.4 [0.2-1.0] -0.1 0.083 0.21 
HbA1c 453 6.6 [6.1-7.5] 6.7 [6.1-7.5] 6.6 [6.1-7.4] 0.047 0.89 0.59 
Triglycerides* § 
(mmol/l) 456 1.5 [1-2.1] 1.4 [1.1-2.1] 1.2 [0.8-1.7] -0.08 0.03 0.015 
HDL-cholesterol* 
(mmol/l) 452 1.1 [0.9-1.4] 1.1 [0.9-1.3] 1.2 [1-1.4] 0.02 0.02 0.23 
Cholesterol (mmol/l) 455 5.1 [4.2-5.7] 4.9 [4.4-5.7] 4.8 [4.3-5.5] -0.06 0.06 0.35 
SBP (mmHg) 448 140 [127.5-150] 138 [125-150] 
134.5 [120-
150] -1.3 1.2 0.30 
DBP (mmHg) 448 81 [80-90] 86 [80-90] 84 [80-90] 0.25 0.65 0.69 
Insulin Sensitivity* 
(µmol/min/m2 BSA)  449 
562.5[315.2-
753.2] 
545.5[369.2-
810.5] 623[382-857] 0.05 0.04 0.24 
Table B. Influence of rs7903146 genotype on clinical and metabolic variables of patients with newly 
diagnosed type 2 diabetes in the Verona NDDS. *Variables were log-transformed before statistical 
analysis to approximate a gaussian distribution; the coefficient beta and its S.E. refer to log-transformed 
values. § p-value still significant after adjustment for age, sex and BMI. 
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 rs11196205 Additive model 
Phenotype Number GG GT TT BETA SE P  Value 
Risk (A) allele frequency, % 0.52 
   
Number (M/F) 464 (315/149) 108 226 129    
Age (yrs) 464 58 [51.2-64] 60 [52-65] 60 [52-67] 1.2 0.65 0.06 
BMI* (kg/m2) 464 30.3 [26.8-33.5] 
29.4 [26.4-
32.9] 
28.5 [26.4-
32.3] -0.02 0.02 0.21 
Fasting P-glucose § 
(mmol/l) 463 6.7 [5.9-7.6] 7.2 [6-7.9] 7.3 [6.3-8.5] 0.3 0.11 0.009 
2hr P-glucose (mmol/l) 463 13.1 [10.7-15.9] 
13.1 [10.1-
16.4] 
14.3 [11.1-
16.5] 0.41 0.27 0.12 
Fasting insulin* (mU/l) 459 11.7 [6.9-16.8] 
11.6 [7.9-
17.3] 11 [7.7-15.] -0.01 0.04 0.85 
2hr insulin* (mU/l) 426 61.4 [35-99.7] 
66.1 [44.1-
100] 
61.7 [35.2-
93.2] -0.02 0.05 0.7 
Insulinogenic Index   
(mU/mmol)* 411 4.3[2.1-6.4] 3.7 [2-6.7] 3.5 [2-6.8] -0.04 0.07 0.51 
CIR120’ *(mUxL/mmol2) 425 0.5 [0.24 –1.1] 
0.6 [0.3-
1.4] 0.4 [0.2-1.1] -0.06 0.08 0.5 
HbA1c 453 6.6 [6-7.4] 6.7 [6.1-7.5] 6.6 [6.2-7.6] 0.04 0.09 0.66 
Triglycerides* (mmol/l) 456 1.4 [1-2] 1.4 [1-2.1] 1.4 [0.9-1.8] -0.02 0.03 0.58 
HDL-cholesterol* 
(mmol/l) 452 1.1 [1-1.4] 
1.1 [0.9-
1.3] 1.1 [1-1.4] -0.002 0.02 0.92 
Cholesterol* (mmol/l) 455 5.1 [4.2-5.9] 5 [4.3-5.6] 4.9 [4.4-5.4] -0.09 0.06 0.15 
SBP (mmHg) 448 140 [126-150] 
138 [128-
150] 
140 [120-
150] -1.3 1.2 0.29 
DBP (mmHg) 448 85 [80-90] 85 [80-90] 84 [80-90] -0.17 0.62 0.77 
Insulin Sensitivity* 
(µmol/min/m2 BSA) 449 
610 [351-
781] 
532 [328-
788] 
598 [383-
830] 0.02 0.04 0.52 
Table C. Influence of rs11196205 genotype on clinical and metabolic variables of patients with newly 
diagnosed type 2 diabetes in the Verona NDDS. *Variables were log-transformed before statistical 
analysis to approximate a gaussian distribution; the coefficient beta and its S.E. refer to log-transformed 
values. § p-value still significant after adjustment for age, sex and BMI. 
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 rs12255372 Additive model (dominant model) 
Phenotype Number GG GT TT BETA SE P  Value 
Risk (A) allele frequency, % 0.39 
   
Number (M/F) 464 (315/149) 167 225 72    
Age (yrs) 464 59 [51-65] 59 [52-65] 60 [52-67] 0.85 0.67 0.20 
BMI* § (kg/m2) 464 30.1 [26.9-33.5] 
28.7 [26.1-
32.4] 
28.7 [26.1-
32.9] -0.03 0.01 (0.023) 
Fasting P-glucose 
(mmol/l) 463 6.8 [5.9-7.8] 7.2 [6.3-8.0] 7.3 [6-8.7] 0.21 0.11 0.073 
2hr P-glucose (mmol/l) 463 13.1 [10.7-16.1] 
13.4 [10.2-
16.2] 
13.2 [10.5-
16.7] 0.14 0.28 0.6 
Fasting insulin* (mU/l) 459 11.8 [7.0-17.1] 
11.6 [8.0-
16.8] 10 [6.8-13.8] -0.03 0.04 0.44 
2hr insulin* (mU/l) 426 69.8 [38.2-103.5] 
61.4 [41.8-
97.3] 
64 [32.6-
92.6] -0.06 0.05 0.24 
Insulinogenic Index*   
(mU/mmol) 411 4.1[2.1-6.4] 3.6 [1.9-6.9] 3.7 [2-6.1] -0.07 0.07 0.33 
CIR120’ (mUxL/mmol2) 425 0.5 [0.24 –1.2] 0.5 [0.2-1.3] 0.4 [0.2-1] -0.04 0.08 0.64 
HbA1c 453 6.7 [6.1-7.5] 6.7 [6.1-7.4] 6.6 [6.1-7.5] 0.05 0.9 0.53 
Triglycerides* (mmol/l) 456 1.4 [1-2] 1.4 [1-2.1] 1.4 [0.9-1.8] -0.04 0.03 0.24 
HDL-cholesterol* 
(mmol/l) 452 1.1 [0.9-1.4] 1.1 [1-1.3] 1.1 [1-1.4] -0.003 0.02 0.87 
Cholesterol* (mmol/l) 455 5.1 [4.2-5.7] 5 [4.4-5.7] 4.8 [4.2-5.5] -0.06 0.07 0.34 
SBP (mmHg) 448 140 [130-150] 
138 [124-
150] 
130 [120-
150] -2 1.2 0.1 
DBP (mmHg) 448 85 [80-90] 85 [80-90] 84 [80-90] -0.4 0.65 0.5 
Insulin Sensitivity* 
(µmol/min/m2 BSA) 449 
547 [327-
768]] 
544 [355-
797] 
648 [409-
875] 0.07 
0.04
4 0.12 
Table D. Influence of rs12255372 genotype on clinical and metabolic variables of patients with newly 
diagnosed type 2 diabetes in the Verona NDDS. *Variables were log-transformed before statistical 
analysis to approximate a gaussian distribution; the coefficient beta and its S.E. refer to log-transformed 
values. § p-value still significant after adjustment for age, sex and BMI. 
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